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Abstract 
Background: Conjugated linoleic acid (CLA) refers to a group of positional and 
geometric isomers of linoleic acid (LA) mainly found in the meat and dairy products of 
ruminants. CLA has been shown to possess different biological activities such as anti-
carcinogenic and anti-atherogenic properties, and also to influence body weight, energy 
and lipid metabolism, immune response, and inflammation. The endocannabinoid 
system (ECS) is involved in a variety of physiological processes, including the 
regulation of feeding behavior and energy homeostasis. ECS includes neuromodulatory 
archidonate-based lipids, the best characterized are 2-arachidonoyl-glycerol (2-AG) and 
N-arachidonoylethanolamine (AEA or anandamide), which activate specific 
cannabinoid receptors (CB1 and CB2). N-oleoylethanolamide (OEA) and N-
palmitoylethanolamide (PEA) are generally termed as endocannabinoid-related 
compounds. OEA has been shown to decrease food intake and body weight gain, while 
PEA is known to possess anti-inflammatory activity. Conversely to endocannabinoids, 
OEA and PEA don’t exert their actions by activating cannabinoid receptors, but mostly 
through binding the peroxisome proliferator activated receptors (PPARs).  
Methodology: The aim of the present thesis was to evaluate the effects of dietary intake 
of CLA on fatty acid metabolism, tissue fatty acid incorporation and endocannabinoid 
biosynthesis in liver of obese Zucker rats and in plasma of healthy volunteers. 32 male 
rats were fed with an equimolar mix of c9,t11 and t10,c12 CLA isomers (about 1%) 
supplemented or not with two different background diets, one based on fat of vegetal 
origin, PO, and the other made with a fat content of animal origin, OF. Treatment lasted 
3 months. In a randomized cross-over study we also evaluated the effects of very high 
doses of CLA on lipid profile and endocannabinoid levels in plasma of 24 healthy men 
and women (aged 18 to 65) who consumed each three distinct diets for three weeks. 
Diets were identical except for 7% of total energy (approximately 20 g/day) which was 
provided either by: CLA isomers (80% c9,t11 and 20% t10,c12), industrial trans fatty 
acids, or oleic acid (OA).  
Principal Findings: In Zucker rats, irrespective of the background diet CLA affected 
body and liver weight, with a reduced hepatic lipid deposition. CLA intake increased 
concentration of arachidonic acid (AA) with both PO or OF diets, and docosahexaenoic 
acid (DHA) only when CLA was included in the OF diet. CLA feeding in combination 
with PO diet only, increased retinol level. CLA intake resulted in a decrease of ∆9 
desaturase index, which was inversely correlated to n-3 highly unsaturated fatty acid 
(HUFA) score in OF diet. In human plasma, CLA compared to OA diet decreased the 
metabolism and the incorporation of the LA metabolites, and influenced alpha linolenic 
acid (ALA) metabolism, which resulted in an increased n-3 HUFA score. Also, we 
confirmed as high doses of CLA reduced elongation of long chain fatty acids (LCFAs). 
CLA intake did not cause significant changes in the profile of endocannabinoids in liver 
of Zucker rats and in human plasma, but we found increased levels of PEA in OFCLA 
fed rats, and OEA in both OF and PO background diets supplemented with CLA.  
Conclusions: Based on our results, we conclude that the effects of CLA on fatty acid 
metabolism and endocannabinoid biosynthesis are strongly influenced by the 
background diet, which may also explain the differences found between experimental 
animals and humans. By improving n-6/n-3 HPUFA balance and sustaining PPARα 
activity, directly and indirectly through OEA and PEA, CLA may exert its beneficial 
actions on human health and protection against some diseases, especially those 
characterized by chronic inflammation due to an impaired body fat deposition. 
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1. Introduction 
For many years, the research in the fields of nutrition and food science has been 
specifically focused on the safety and toxicity of foods in relation to their conservation, 
as well as for obtaining the proper nutritional requirements to maintain an optimal state 
of health. Today, however, the quality and quantity of food intake is seen as a possible 
mean to preserve health in humans at different times in life, when physiologically, some 
nutritional needs are different (growth, pregnancy, lactation, special conditions of stress, 
etc.) and to slow or prevent the onset of chronic and degenerative diseases that are on 
the rise, also due to the elongation of life expectancy. This implies the recognition and 
characterization of substances in foods with specific biological activities and the study 
of their action in different physiological and pathological conditions. Once the target 
population suitable to these biologically-active compounds has been determined, the 
natural application of biotechnology research is the formulation of products enriched in 
these substances, the so-called functional foods. They are not necessarily "built" foods, 
more often are foods already present in our diet, but for technology and marketing needs 
have never been considered. Nutrition research is increasingly interested in the 
identification and characterization of molecules naturally present in foods with 
beneficial properties for human health. Of remarkable interest has been the discovery of 
the biological properties of a particular group of fatty acids, the conjugated linoleic 
acids (CLAs). These unusual fatty acids have shown multiple positive activities in 
different experimental models. Dairy products are particularly rich in CLA. The 
understanding of the mechanisms by which CLA exerts its protective effects against 
many diseases, appears to be important not only from a scientific point of view, but 
would also be an incentive to the daily consumption of foods rich in this fatty acid by 
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those sections of the population more exposed to the onset of diseases. The influence of 
dietary fatty acids on the endocannabinoid system (ECS) represents an emerging and 
interesting matter of study for nutrition research, in fact ECS is deeply involved in a 
variety of physiological mechanisms, including the control of feeding behavior, energy 
balance, and energy homeostasis.  
There are no many studies and experimental data published in literature about the 
influence of CLA on endocannabinoid metabolism, and the aim of the present thesis is 
to investigate the impact of dietary CLA intake on fatty acid metabolism and 
endocannabinoid biosynthesis in an animal model of obesity, the fatty Zucker rat, and in 
healthy subjects. 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 9
1.1 Conjugated linoleic acid (CLA) 
Conjugated linoleic acid (CLA) refers to a group of at least 28 positional and geometric 
isomers of linoleic acid (LA, 18:2 c9,c12). These fatty acids are characterized by a 
carbon chain containing conjugated double bonds. These double bonds may be found 
from position ∆6 to position ∆13, in cis (c) or trans (t) configuration. The different 
combinations lead to the formation of different isomers, however, in nature and in 
synthetic blends the most abundant are the c9,t11 CLA and t10,c12 CLA isomers 
(Fig.1), which showed different biological activities. The predominant isomer found in 
foods is the c9,t11 CLA, also called as rumenic acid (RA). CLA isomers are mainly 
found in the meat and dairy products derived from ruminants (1). The presence of CLA 
in dairy products is due to a biochemical process called biohydrogenation, which takes 
place in the rumen of ruminant animals by fermentative activity of the anaerobic 
bacterium Butyrivibrio fibrisolvens (2). 
 
 
Figure 1. Chemical structure of the main CLA isomers c9,t11 and t10,c12, 
compared to linoleic acid (LA, 18:2 c9,c12). 
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The biohydrogenation (Fig.2) consists of several enzymatic reactions, one of them is 
catalyzed by the enzyme linoleic isomerase and implies an isomerization reaction where 
LA is directly converted into CLA isomers. Other fatty acids with 18 carbon atoms and 
double bonds in position ∆9 and ∆12 of the carbon chain, such as alpha linolenic acid 
(ALA, 18:3 c9,c12,c15) and gamma linolenic acid (GLA, 18:3 c6,c9,c12), can be 
converted into CLA through multiple reactions. These reactions involve the activity of 
enzymatic isomerases, and lead to the formation of conjugated double bond fatty acids. 
These intermediates are converted into vaccenic acid (VA, 18:1 t11) by other enzymes 
called reductases. VA can undergo further chemical reduction of the double bond in 
position ∆11, which determines the formation of the stearic acid (SA, 18:0). 
Alternatively, part of the produced VA can be absorbed in the intestine and transported 
into the tissues, where it is desaturated to c9,t11 CLA isomer. This biochemical 
conversion represents the main pathway responsible for the formation of c9,t11 CLA 
isomer in cow’s milk (3). Several studies led to identify the endogenous synthesis of 
c9,t11 CLA from VA in animals, and were also definitely confirmed in humans (4,5), 
through the activity of the enzyme ∆9 desaturase (6,7). The presence of small amounts 
of CLA and other fatty acids with conjugated double bond in many foods of plant origin 
such as margarine, can be explained by a process of partial hydrogenation of industrial 
origin. In the absence of oxygen, unsaturated fatty acids (UFAs) undergo the addiction 
of hydrogen to the double bonds, and the subsequent recombination of them leads to the 
formation of conjugated double bonds (8). 
 
 
 11
18:2 c9,t11
C L A
Vac c enic  Ac id
18:1 t11
Δ 9 Des aturas e
L inoleic   Ac id
18:2 c9,c12
(tis s ue)
Alpha-L inolenic  Ac id
B iohydrog enation
(rumen)
18:3 c9,c12,c15
R educ tas e
+2H
Is omeras e
Is omeras e
G amma-L inolenic  Ac id
18:3 c6,c9,c12
S tearic  Ac id
18:0
OHO
OHO
OHO
OHO
OHO
OHO
R educ tas e
+2H
R educ tas e
+2H
 
Figure 2. Synthesis of CLA and vaccenic acid (VA, 18:1 t11) from 
different polyunsaturated fatty acids by biohydrogenation. 
 
 
 
 
 
 
 
 
 
 
 12
1.2 Dietary sources of CLA 
The main sources of CLA in the human diet are represented by dairy products like milk 
and cheese, and meat of ruminants (9), which provide about 0.4 g/day (10). The main 
isomer found in these foods is the c9,t11 CLA, whereas the t10,c12 isomer is present in 
trace amount (3). Concentration of CLA in dairy products typically ranges from 2.9 to 
8.9 mg/g fat, with c9,t11 isomer representing from 73% to 93% of total CLA. 
Homogenized cow's milk typically contains 5.5 mg/g fat. Low-fat yogurt has 4.8 mg/g 
fat, butter 4.7 mg/g fat and cottage cheese 4.5 mg/g fat. Other types of cheese, as well as 
ice cream and sour cream, are also good sources of CLA. Grass-fed cows produce milk 
with the highest CLA content (11), but a grain diet supplemented with full-fat rapeseed 
or soybean concentrate increases CLA (12). Aged cheese generally has lower amounts 
than cheese with a shorter ripening period, while processed cheese contains higher 
amounts (12). Beef also has CLA in a similar range as dairy products, with the c9,t11 
isomer contributing from 57% to 85% of total CLA (9,13,14). Ground beef has 4.3 
mg/g fat of CLA. Lamb typically contains 5.6 mg. Meats from chickens and pigs, non-
ruminants, contain small amounts under 1 mg per gram of fat. CLA in meat is not 
destroyed by cooking (12). Vegetable oils and margarine have small amounts of CLA, 
about the same as the meat of non-ruminant animals and birds. The amount typically 
ranges from 0.6 to 0.9 mg/g fat (9). CLA is claimed to cause weight loss and reduce fat 
mass (15-18), mixtures of c9,t11 and t10,c12 CLA are produced by industrial process 
and sold in health food stores as supplements, especially as muscle builder used by 
athletes in gyms. In these supplements, chemically synthesized CLA consists for most 
of c9,t11 and t10,c12 CLA isomers present in equal amounts (50:50), and in the form of 
either free fatty acids (FFAs) or triacylglycerols (TAGs). 
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1.3 Dietary intake in humans 
The recommended daily amount of total CLA in human diet should be about 0.15 and 
0.2 g for women and men, respectively (19,20). About 60% of the CLA intake is 
derived from dairy products and 37% from meat products. The c9,t11 CLA isomer that 
represents about 90% of the total CLA intake has been estimated to be about 190 and 
140 mg/d for men and women, respectively (19). There is no relationship between body 
composition and total CLA or c9,t11 isomer intake, suggesting that dietary CLA has 
little effect on body composition in humans (19). The effects of CLA on body weight 
and body fat in humans were considerably less than those seen in mice, although the 
doses of CLA used in mouse and human were comparable (21). 
It has been shown that diets rich in high-fat dairy foods (and thus containing c9,t11 
CLA) significantly influence both lipid and c9,t11 CLA concentrations in human milk 
(22). In men, c9,t11 CLA intake correlates with TAG c9,t11 CLA content, suggesting 
that TAG c9,t11 CLA may serve as a biomarker for c9,t11 CLA intake. In females, 
there are no correlations between c9,t11 CLA intake and the c9,t11 CLA content of any 
esterified plasma lipid fraction. In neither sex there is a relation between dietary c9,t11 
CLA intake or plasma c9,t11 CLA concentration and circulating lipoprotein cholesterol 
level (23). Although some adverse effects of CLA intake on liver function are reported 
in multiple studies, including different animal models (24-26), a very high daily intake 
of CLA did not produce clinically relevant effects on markers of liver and kidney 
function in healthy volunteers (27). High intake of an 80:20 mixture of c9,t11 CLA and 
t10,c12 CLA raised the total to high density lipoprotein (HDL) cholesterol ratio in 
healthy subjects (28). 
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1.4 CLA metabolism 
The current knowledge regarding the CLA metabolism has been developed primarily 
through studies carried out in animal models. In the phospholipid (PL) fraction of lamb 
liver naturally exposed to a diet rich in CLA, were found different fatty acids with a 
structure of conjugated dienes (CD) such as conjugated linolenic acid (CD 18:3), 
conjugated eicosatrienoic acid (CD 20:3), and conjugated arachidonic acid (CD 20:4) 
(29). These experiments demonstrated that CLA is metabolized in a manner similar to 
LA, and competes for the same enzyme system (Fig.3). The CLA can undergo 
desaturation reaction by the enzyme named ∆6 desaturase, the subsequent elongation of 
the carbon chain by the elongase, and finally a further desaturation by the ∆5 desaturase, 
while preserving the structure of conjugated double bonds (25,30). 
 
18:2 (Δ c9,c12)
Linoleic Acid
18:3 (Δ c6,c9,c12)
20:3 (Δ c8,c11,c14)
20:4 (Δ c5,c8,c11,c14)
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-2H
-2H
+2C
Δ 6 Desaturase
Δ 5 Desaturase
Elongase
CD 18:2 (Δ c9,t11)
CLA
CD 18:3 (Δ c6,c9,t11)
CD 20:3 (Δ c8,c11,t13)
CD 20:4 (Δ c5,c8,c11,t13)
Conjugated Arachidonic Acid
16:2
β -ox 
perox.
16:3
β -ox 
perox.
CD 16:2
β -ox 
perox.
β -ox 
perox.
CD 16:3
 
Figure 3. Metabolism of CLA (c9,t11) and linoleic acid (LA, 18:2 c9,c12). 
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These findings were also confirmed in other experimental models and in human studies 
(31). CLA and its metabolites CD 18:3 and CD 20:3 are mainly incorporated in the 
neutral lipids, while the CD 20:4 is predominantly found in the PLs, as well as the 
metabolites produced from LA, GLA, 20:3 c8,c11,c14, and arachidonic acid (AA, 20:4 
c5,c8,c11,c14). The different incorporation into lipids can be explained by the 
increasing of double bonds with the cis configuration that facilitates the incorporation 
into PLs, while the conjugated diene structure favors the incorporation into neutral 
lipids. The presence of double bonds with cis configuration into CD 20:4 appears more 
decisive than the conjugated double bonds, making this CLA metabolite more suitable 
for incorporation into PLs. Significant changes in the levels of LA metabolites (GLA, 
20:3 c8,c11,c14, and AA) were observed only in adipose tissue and in mammary gland, 
which are very rich in neutral lipids (32). 
A crucial aspect of the CLA metabolism is to understand if the competition of CLA 
with LA occurs at the enzymatic level or as incorporation. It is likely that CLA 
competes across the two modes. Enzymatic competition takes place at the level of the 
liver, while in the extra hepatic tissues there is competition as incorporation. It has been 
shown that in those tissues rich in neutral lipids, CLA is able to decrease the 
concentration of the LA metabolites, but not in liver, where CD 20:4 has not been found 
(33). Also, since the presence of CD 20:4 and LA are correlated, it is likely that CLA 
modulates the formation and incorporation of the LA metabolites, such as GLA, 
eicosatrienoic acid (20:3), and AA (all substrates for the biosynthesis of eicosanoids), 
replacing them with its metabolites (CD 18:3 and CD 20:3), which are able to inhibit 
the metabolic pathways of cyclooxygenase (COX) and lipoxygenase (LOX), resulting in 
a reduction of the eicosanoid biosynthesis (34). 
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It has been demonstrated that CLA and its metabolites accumulate in rat tissues in a 
dose dependent manner, and AA significantly decreased, suggesting that the effects 
explicated by the CLA metabolism may interfere with the metabolism of eicosanoids 
(33). Fatty acid oxidation also occurs in peroxisomes, when the fatty acid chains are too 
long to be handled by the mitochondrial enzymes. Eicosanoids (35), isoprostanes (36), 
and AA (37) undergo β-oxidation at the level of peroxisomes. Even for the biosynthesis 
of docosahexaenoic acid (DHA, 22:6 c4,c7,c10,c13,c16,c19) is required the 
peroxisomal β-oxidation (38). CLA and CD 20:4 are converted to CD 16:2 and CD 16:3 
through β-oxidation in peroxisomes (39). 
The metabolism of CLA has been ascertained only for the isomers c9,t11 and t10,c12, 
while for the other isomers is assumed a different metabolism (30). Compared to the 
c9,t11, the t10,c12 CLA isomer appears able to generate larger amounts of 18:3 
c6,t10,c12 and less of 20:3 c8,t12,c14, this may depend on the difficulty in elongation 
of 18:3 c6,t10,c12 (40). In both rat and human, the t10,c12 CLA isomer is converted by 
∆6 desaturase activity into CD 18:3, but it was not found CD 20:3. Opposite, the CD 
20:3 produced from c9,t11 CLA isomer is found in high concentrations (40). The 
presence of the CD 20:4 seems instead to be correlated to low concentrations of LA in 
the diet (30).  
CLA is able to influence lipid metabolism by altering the fatty acid composition of the 
cell membrane through the reduction of monounsaturated fatty acids (MUFAs). CLA 
directly reduces the activity of ∆9 desaturase enzyme rather than influencing its protein 
or mRNA syntheses (41). Such activity is estimated by the index of desaturation that is 
calculated by the palmitoleic acid (16:1 c9)/palmitic acid (PA, 16:0), and the oleic acid 
(OA, 18:1 c9)/SA ratios. A balanced ratio between MUFAs and saturated fatty acids 
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(SFAs) is important to preserve the fluidity of the cell membrane. Unbalanced 
MUFA/SFA ratio can lead to significant changes of insulin sensitivity (42), metabolic 
rate (43), and determine conditions such as obesity (44). A mixture of equal amounts of 
c9,t11 and t10,c12 CLA isomers added to a diet based on fat of vegetal origin, palm oil, 
compared to a diet made with fat of animal origin, ovine fat, and enriched with the same 
CLA mixture, improved serum profile of adipokines and inflammatory markers in obese 
Zucker rats (45). Rats fed with diets enriched in CLA exhibited lower daily feed intake, 
final body and liver weights, and hepatic lipid content. Total and low density lipoprotein 
(LDL) cholesterol levels were increased in CLA supplemented groups. CLA also 
promoted higher adiponectin and lower plasminogen activator inhibitor-1 (PAI-1) 
serum concentrations. In contrast to palm oil diets, ovine fat increased insulin resistance 
and serum levels of leptin, tumor necrosis factor alpha (TNFα) and interleukin-1beta 
(IL-1β). Adipose tissue from epydidimis and retroperitoneum  showed similar 
deposition of individual fatty acids. The analysis showed that t10,c12 CLA isomer was 
highly associated with adiponectin and PAI-1 levels.  
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1.5 Biological activities of CLA isomers 
At the end of the 80s, the anti-carcinogenic properties of CLA were identified (46,47), 
since then, more and more scientists and studies investigated on the biological 
properties exerted by this group of unusual fatty acids. 
The physiological effects and the benefits on human health exerted by CLA isomers can 
be summarized in five main biological activities: 
• Effects on body weight and composition; 
• Influence on lipid metabolism, beneficial effects for prevention and treatment of 
obesity and diabetes;  
•  Anti-atherosclerosis activity; 
• Anti-carcinogenic properties; 
• Immune response modulation and anti-inflammatory activity.  
The various biological effects reported for CLA cannot be explained by a single 
biochemical mechanism. A major direct line of support for this conclusion is that the 
t10,c12 and c9,t11 CLA isomers appear to produce different effects (48). For example, 
the t10,c12 isomer of CLA shows at the same time anti-carcinogenic, anti-obese and 
anti-diabetic effects, whereas the c9,t11 CLA isomer essentially exerts an anticancer 
effect (49). 
Even those effects that are clearly attributed to a single isomer may not all be caused by 
the same biochemical mechanism. For example, it has been reported evidence indicating 
that t10,c12 CLA directly inhibits the activity of stearoyl-CoA desaturase (SCD) (48). 
Moreover, it is difficult to imagine how this finding alone could explain the range of 
physiological effects associated to this CLA isomer. Of the two major isomers of CLA, 
t10,c12 is specifically responsible for the antiobesity effects (50-52). 
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1.5.1 Effects of CLA on body weight, influence on energy and lipid 
metabolism, adipogenesis, inflammation and apoptosis. 
In the first study that has shown the capacity of CLA to influence body composition in 
animals, male and female mice fed with a 0.5% (w/w) CLA mixture had 57% and 60% 
lower body fat mass (BFM), respectively, compared to controls (53). Subsequently, 
other studies showed as CLA supplementation was able to reduce BMF in mice, rats, 
and pigs (54,55). 
There are some contradictory results about the ability of CLA to reduce BFM in humans. 
For example, supplementation of CLA in overweight and obese people (3–4 g/day for 
24 weeks) decreased BFM and increased lean body mass (LBM) (56), while healthy 
adults supplemented with a CLA mixture in yogurt (3.76 g/day for 14 weeks) had no 
effect on body composition (57). 
CLA mixture composition, individual CLA isomer used, dose, time of treatment, gender, 
weight, age and metabolic status of the subjects, are all factors that can explain the 
contradictory results obtained in human trials. Primarily, the dose of CLA administered 
in animal and human studies may underlie the differences of the obtained results. 
Overweight subjects supplemented with a mixture of CLA isomers (3.76 g/day for 14 
weeks) had not decreased body weight, body mass index (BMI), or BFM (57), in 
contrast, mice supplemented with 1.5% (w/w) CLA mixture for 4 weeks weighed 
significantly less and had reduced adiposity, compared to controls (58). Referring to 
body weight, the administered dose of CLA in mice was 20 times than that administered 
to humans. The biochemical mechanisms underlying the anti-obesity effect of CLA are 
multiple. CLA decreases energy intake in animal models (53,59,60) but this has not 
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been demonstrated in humans (61,62). CLA could exerts a direct effect on hypothalamic 
appetite-regulating genes (60,63). 
It has been proposed that CLA might reduce adiposity by elevating energy expenditure 
via increased basal metabolic rate (BMR), thermogenesis, or lipid oxidation in animals 
(64,65). Mice fed t10,c12 CLA isomer also showed increased β-oxidation in 
differentiating mouse preadipocytes (66), and expression of the mitochondrial protein 
responsible for transferring fatty acids into mitochondria, carnitine palmitoyltransferase 
1 (CPT1) in white adipose tissue (67). The regulation of the energy expenditure in 
human studies by CLA, showed different results, with no reported changes in BMR or 
BMF (62), or higher basal metabolic rate although body weight was not affected (57). 
Only one study reported both increased energy expenditure and decreased body weight 
in subjects supplemented with a CLA mixture (68). 
Other studies have demonstrated that supplementation with mixed CLA isomers 
increases LBM associated with higher levels of energy expenditure, in healthy obese 
humans (69). CLA could enhance LBM by increasing bone or muscle mass (70). Some 
studies reported that CLA suppresses preadipocyte differentiation in animal (50,66,71) 
and human (72). It has been shown that t10,c12 CLA isomer treatment suppressed 
adipogenesis and lipogenesis, reduced preadipocyte differentiation and promoted 
maintenance of mature adipocytes, specifically by reducing sterol regulatory element 
binding protein 1c (SREBP-1c), peroxisome proliferator-activated receptor gamma 
(PPARγ), liver X receptor (LXRα), CCAAT-enhancer-binding protein alpha (C/EBPα), 
and adipocyte fatty acid binding protein (aP2) expression (73-75).  
t10,c12 CLA isomer supplementation decreased the expression of PPARγ and its target 
genes in animal models (67,76,77) and in vitro studies (50,78).  
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In adipogenesis, PPARγ activity may be regulated by phosphorylation, which can be 
mediated by the mitogen activated protein kinase (MAPK) (79). Phosphorylation of 
PPARγ2, that leads to adipocyte differentiation, may decrease its activity by 
ubiquination and proteasome degradation (80), and by reducing both its ligand-
dependent and ligand-independent transactivating functions (81). t10,c12 CLA 
increases PPARγ phosphorylation (78) without significantly decrease its protein levels, 
suggesting that the subsequent downregulation of PPARγ target genes is due to 
decreased transactivating function.  
After CLA stimulation, extracellular signal regulated kinase (ERK) phosphorylation 
occurs and leads to inactivation of  PPARγ, suppression of adipogenic gene expression 
and insulin-stimulated glucose uptake (82). t10,c12 CLA increased expression of 
proinflammatory cytokines (83) by nuclear factor kappa-light-chain-enhancer of 
activated B cells (NFκB) activation in adipocytes. NFκB may also repress PPARγ 
activity by the interaction with the DNA-bound retinoid X receptor (RXR)-PPARγ 
heterodimer.  
Pro-inflammatory cytokines produced by adipose tissue, can cause insulin resistance, 
suppressed lipid synthesis and increased lipolysis in adipocytes. It has been reported 
that t10,c12 CLA supplementation increased the expression or secretion of interleukins 
IL-6 and IL-8 in adipocyte cultures (76,67,82), TNFα and IL-1β, suppressing PPARγ 
activity and insulin sensitivity (58,77,78,84). 
In human subjects, t10,c12 CLA increases the levels of inflammatory prostaglandins 
(PGs) (69), and  the expression of cyclooxygenase 2 (COX-2), an enzyme involved in 
the synthesis of PGs in differentiated human adipocytes (71). Also, t10,c12 CLA 
increased PGF2α secretion in human adipocytes (83), a prostaglandin able to inhibit 
 22
adipogenesis via phosphorylation of PPARγ by MAPKs (85), and through activation of 
the hypoxia inducible factor-1 (HIF-1) responsible for decreasing PPARγ and C/EBPα 
expression.  
Supplementation with mixed isomers of CLA or t10,c12 CLA alone reduced various 
proteins involved in lipogenesis: acetyl-CoA carboxylase (ACC), lipoprotein lipase 
(LPL), SCD, and fatty acid synthase (FAS) (67,72,82,86). t10,c12 CLA may exert its 
anti-lipogenic effects by the repression of the transcription factor SREBP-1 and its 
target genes.  
It has been reported hyperinsulinemia associated with insulin resistance in animals (67) 
and humans (87,88) after supplementation with a CLA mixture or t10,c12 CLA isomer 
alone. CLA can determine inhibition of insulin signaling by activation of inflammatory 
pathways and stress kinases, and  down regulating the expression of some genes 
involved in the insulin signaling and glucose uptake pathways (suppression of glucose 
transporter type 4 or GLUT4) (71,82). In addition, some in vitro studies (71,76) 
suggested that CLA may inhibit insulin signaling by increasing the expression of the 
suppressor of cytokine signaling (SOCS)-3. SOCS-3 impairs insulin signaling and 
glucose uptake by promoting the phosphorylation of the inhibitory serine 307 on insulin 
receptor substrate 1 (IRS-1), leading to its ubiquination and proteasome degradation 
(89). t10,c12 CLA treatment also showed to decrease the protein levels of important 
signaling proteins for insulin sensitivity such as insulin receptor (IR) β and IRS-1 (76). 
t10,c12 CLA may cause insulin resistance decreasing expression of the insulin-
sensitizing hormone adiponectin (76,82). Adiponectin is a target gene of PPARγ (90), 
so, its suppression may be conducted, almost in part, to the activity of t10,c12 CLA in 
antagonizing PPARγ.   
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In mice and human adipocytes, acute treatment with mixed CLA isomers or t10,c12 
CLA alone increased lipolysis, releasing FFAs and glycerol from stored TAGs through 
the action of the hormone-sensitive lipase (53,86,91). On the other hand, studies carried 
out by animal models have demonstrated that chronic supplementation with a mixture 
of CLA had no effect on lipolysis (92,93). In contrast, chronic treatment with mixed 
CLA isomers reduced glycerol release from isolated rat adipocytes (94). FFA levels 
have been reported to be lower in serum of OLETF rats supplemented with a CLA 
mixture [1.0% (w/w) for 4 weeks], compared to controls (95).  
CLA may be able to reduce BFM by apoptosis. Supplementation with t10,c12 CLA or 
CLA mixture showed to stimulate apoptosis in mice (64,67) and murine adipocytes (96).  
CLA may exert its effect on apoptosis enhancing TNFα gene expression in white 
adipose tissue, and increasing the ratio of BAX relative to Bcl2, an inducer and 
suppressor of apoptosis in the  mitochondrial apoptotic pathway, respectively (77). 
t10,c12 CLA treatment in mice and murine adipocytes increased the mRNA levels of 
genes involved in the integrated stress response (ISR), such as activating transcription 
factor 3 (ATF3), C/EBP homologous protein (CHOP), pseudokinase tribbles 3/SKIP 3 
(TRIB3), X-box binding protein (XBP-1), and growth arrest and DNA damage 
inducible protein (GADD34) (74). 
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1.5.2 Anti-atherosclerosis activity. 
Several studies have attributed to dietary CLA an antiatherogenic activity with a 
reduction of the atherosclerotic plaque in animal models. 
CLA affects initiation and progression of the atherosclerotic lesions in rabbits through 
its effect on lipid peroxidation (97). Feeding rabbits with an atherogenic diet and 
supplemented with 0.5g CLA/day for 22 weeks, significantly lowered plasma levels of 
triglyceride, LDL-cholesterol, and LDL-cholesterol /HDL-cholesterol ratio, compared 
to control animals. CLA feeding also resulted in fewer aortic fatty lesions (97). 
Subsequent studies using other animal models of atherosclerosis, such as the ApoE−/− 
mouse, have also demonstrated that an 80:20 isomeric CLA mixture induced regression 
of pre-established atherosclerosis (98,99). The study with ApoE−/− animal model 
involved the administration of a 1% cholesterol diet for 8 weeks to induce 
atherosclerosis, followed by a further administration for 8 weeks of 1% cholesterol 
alone or 1% cholesterol  supplemented with isomeric 1% CLA mixture.  
ApoE−/− mice fed CLA blend supplemented diet showed a 30% decrease of lesion area. 
CLA reduced the levels of plasma total cholesterol, LDL- and very-low density 
lipoprotein (VLDL) cholesterol, and TAGs in hamsters. There was no effect on HDL- 
cholesterol, compared to controls (100). CLA fed hamsters also developed 45% fewer 
aortic fatty streaks than control animals. CLA reduced the development of early aortic 
atherosclerosis to a greater degree than LA did, possibly through changes in LDL 
oxidative susceptibility in hypercholesterolemic hamsters. 
Rats fed with CLA (2.3 energy % level) did not show a cholesterol lowering effect on 
serum and liver in contrast to the hypocholesterolemic observation in rabbits (101). LA 
in liver cardiolipin was reduced by CLA. The decrease of LA in cardiolipin of heart 
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mitochondrial membrane diminished heart cytochrome C oxidase activity, that required 
cardiolipin as an activator. These results (101) suggested that modified fatty acid 
composition in liver cardiolipin might influence mitochondrial respiratory function in 
liver. The antiatherogenic effect of CLA could be explained by lowering hepatic 
cholesterol (102), reducing synthesis of cholesterol by the liver (103), or through its 
ability to inhibit the production of PGE2 (101), thromboxanes (104), and platelet 
aggregation (105). It has been hypothesized that the ability of CLA to reduce the 
formation of atherosclerotic plaque could be due to changes in the susceptibility of LDL 
to be oxidized (106). CLA may also act by altering size and lipid composition of 
lipoproteins (107,108). Some studies showed that c9,t11 CLA was the key isomer 
involved in the impediment of the atherosclerosis development, with c9,t11 CLA fed 
mice exhibiting reduced plasma cholesterol and glucose, and reduced lesional area of 
the aorta as well as increased expression of markers of plaque stability (109). 
Cluster of differentiation 68 (CD68), a glycoprotein which binds LDL and expressed on 
monocytes and macrophages, has been identified as a possible target for anti-
atherosclerosis activity of CLA, in fact in the lesions of ApoE−/− mice fed high 
cholesterol diet, it has been shown increased expression of CD68 (98). In contrast, the 
expression of CD68 was significantly decreased in the lesions of mice fed CLA 
supplemented diet, suggesting that CLA intake decreased the infiltration of 
macrophages into the atherosclerotic plaque. Furthermore, CLA inhibited monocyte 
migration through at least two differential mechanisms, one that is PPARγ dependent 
and the other one is PPARγ independent, depending on the chemoattractant used (110). 
Pre-treatment of RAW macrophages with either 50 µM t10,c12 or c9,t11 CLA isomers 
decreased foam cell formation in response to acetylated LDL (ac-LDL) loading (111). 
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Dietary supplementation of CLA did not affect atherosclerosis in mice fed high-
cholesterol (16%, w/w fat and 1.25%, w/w cholesterol) atherogenic diet (112). In this 
study, ApoE−/− mice were fed with a dietary treatment supplemented or not in LA, 
c9,t11 CLA, t10,c12 CLA, or an equimolar mixture of the two CLA isomers, at a 
concentration of 0.5% (w/w). Treatment lasted 12 weeks. t10,c12 CLA caused adverse 
changes in adipocyte function, and plasma and liver lipid metabolism, which are 
partially ameliorated by the administration of c9,t11 CLA.  
There are other studies reporting contradictory results for the potential ant-iatherogenic 
property of CLA, then, further investigations are needed to better elucidate the 
mechanism through CLA may determine regression of atherosclerosis.  
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1.5.3 Anti-carcinogenic properties. 
One of the first studies aimed at assessing the anticancer activity of CLA reported the 
ability of this group of fatty acids to inhibit the initiation phase of carcinogenesis in 
forestomach induced by benzo[a]pyrene (BP),  in mice (113). 
Subsequent studies conducted using mixtures of CLA isomers showed inhibition of 
chemically-induced tumors in mammary gland, skin and colon, in different animal 
models. The inhibition of tumorigenesis was dependent upon the dietary concentrations 
of the CLA mixtures used (0.05 to 1% of the diet), and the timing and duration of CLA 
feeding (114,115). Also, the mechanisms of modulation of CLA were related to the 
stages of initiation, promotion, progression, and metastasis of malignant tumors. CLA 
administered before or after treatment with the carcinogen, prevents tumor evolution. A 
single administration of CLA in the period immediately following weaning and during 
maturation of the mammary gland, seems to be sufficient to protect against chemically- 
induced tumorigenesis (116). Also, CLA is active when administered after the onset of 
the tumor, in this case, however, requires its own continuous supply to achieve the 
maximum inhibition of tumor progression. CLA might act causing changes during the 
development of the mammary gland and making it less susceptible to the neoplastic 
transformation. For example, it has been reported as CLA may act by inhibition of the 
expansion and proliferation of mammary epithelial cells normally susceptible to 
carcinogen-induced transformation (117). Different types of tumors from various organs 
probably respond differently to CLA treatments. The ability of CLA in the prevention 
of tumor process is independent of the amount and type of other fatty acids in the diet 
(118). Few studies conducted in humans have investigated the relationship between 
CLA intake or CLA concentration in tissues and tumor incidence. Female subjects 
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between 55 and 69 years of age,  answered questionnaires regarding the amount of their 
dietary CLA intake, familial incidence of cancer, and other risk factors (119). 
Unexpectedly, this study showed a weak positive relationship between CLA intake and 
breast cancer incidence. A study reported as the levels of serum and dietary CLA were 
significantly lower in breast cancer patients than in control subjects (120). In contrast, 
there was no direct correlation between levels of CLA in breast adipose tissue and 
women with and without breast cancer (121).  
Several studies regarding the growth inhibition of numerous types of tumors, indicate as 
the different CLA isomers have distinct effects on tumorigenesis and lipid metabolism. 
One of these studies (122), showed that purified c9,t11 CLA isomer administered to diet 
either as butter fat or as purified isomer, was as effective as a mixture of CLA isomers 
(0.8%) in reducing mammary epithelial mass, size of the terminal end buds, and 
mammary tumor development induced by N-Nitroso-N-methylurean (MNU). Rats fed 
with diets containing 1% c9,t11 CLA or 2% VA (which can be metabolized to c9,t11 
CLA) for 6 weeks, reduced the MNU-induced tumor by 50%, compared with a control 
group fed regular butter (123). The concentrations of CLA in the tissues and the 
concentration of c9,t11 CLA in the mammary gland were 4-fold greater in the VA 
group than the control group. This means that the rats that were able to convert VA into 
c9,t11 CLA, were able to decrease tumorigenesis. Results from other studies carried out 
in rodents showed that c9,t11 and t10,c12 CLA isomers alone were as effective as the 
CLA isomeric mixture in reducing mammary tumors induced by MNU (124,125). 
Compared to c9,t11 CLA, t10,c12 CLA was more effective in lowering incidence of 
BP-induced forestomach tumors in mice, but the tumor size did not differ between the 
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two isomers (126). Another study conducted in intestinal tumors of mice showed 
opposite results for  t10,c12 CLA (127). 
Mice with mutation of the APC gene that leads to intestine tumors were fed either a diet 
with sunflower and rapeseed oils or a diet supplemented in 1% c9,t11 CLA or t10,c12 
CLA. The sizes of the adenomas were significantly greater in the distal part of small 
intestine in mice fed with the diet containing t10,c12 CLA isomer, compared to the 
control group, suggesting that t10,c12 CLA may act as a growth promoter in small 
intestine carcinogenesis. In vitro studies reported the effects of CLA purified isomers on 
growth, viability, and apoptosis of tumor cell lines from mammary gland, prostate, and 
digestive tract or their metastasis. In most of the studies with mouse and human 
mammary tumor cell lines, c9,t11 CLA did not inhibit tumor cell growth (128), and 
t10,c12 CLA showed a greater growth inhibitory capacity than c9,t11 CLA. Culture 
conditions including concentration of CLA, duration of the treatment, and tumor type as 
well as the cell lines used, seem to determine whether CLA isomers would affect cell 
growth. Also, CLA isomers may reduce tumor cell numbers through different 
mechanisms, one of them involves the estrogen receptor (ER) (129). t10,c12 CLA and 
c9,t11 CLA differentially influence the expression of many genes in mouse liver (130) 
and adipose tissue (131). CLA isomers showed differential effects on fatty acid 
composition into PLs of several tissues, including liver, adipose tissue, heart, spleen, 
and mammary gland (132), leading to alterations in AA availability and therefore 
influencing the metabolism of eicosanoids. In particular, the prostaglandins PGE2 and 
PGF2α by influencing inflammation, cell proliferation, immunity, platelet aggregation, 
and cell differentiation in key tissues (prostate, mammary gland, colon, and skin), may 
modulate tumorigenesis (133). CLA could reduce biosynthesis of eicosanoids through a 
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competition for AA incorporation in PLs (134), as shown in the colonic mucosa (135), 
or inhibition of the expression/activity of the enzymes COX-1 and COX-2. COX-1 is 
the constitutive enzyme in different cell types and produces small amounts of PGE2 for 
the regulation of the cellular homeostasis, while COX-2 is expressed in response to 
inflammatory signals and generates large quantities of PGE2 inducing inflammation. It 
has been shown in vitro studies as CLA decreased the conversation of AA into 
eicosanoid metabolites in the presence of COX-1 (136), and in cultured macrophages 
reduced mRNA and protein levels of COX-2 (137). The association between high levels 
of COX-2 with tumor progression and inhibition of apoptosis (138,139), could explain 
the benefic role of CLA in tumorigenesis.  
Other studies conducted using purified isomers showed as c9,t11 CLA decreased the 
incorporation of AA into phosphatidylcholine and increased AA uptake into 
phosphatidylethanolamine in human breast and colon cell lines (140). In contrast, 
t10,c12 CLA had no effect on AA uptake into breast cells (140). Both isomers were able 
to inhibit cell growth, but only c9,t11 CLA decreased PGE2 production. c9,t11 CLA 
and t10,c12 CLA were both effective in blocking 12-otetradecanoylphorbol-13-acetate 
(TPA)-induced expression of COX-2, compared to cell cultures treated with LA (141). 
In human prostate cancer cell lines, c9,t11 CLA but not t10,c12 CLA increased TNFα-
induced apoptosis (142), decreased prostate cancer cell proliferation, and reduced 
mRNA expression of 5-lipoxygenase (5-LOX) (143). Oppositely, in breast cancer cells 
t10,c12 CLA but not c9,t11 CLA, decreased cell growth and production of 
hydroxyeicosatetraenoic acid (5-HETE) while increasing apoptosis (144).  
These studies suggest that the inhibitory effects on cell growth in tumor cells by c9,t11 
CLA are associated to changes in COX-2 expression, while alternative mechanisms 
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may mediate the effects of t10,c12 CLA isomer. Regarding cell proliferation and 
apoptosis, CLA has shown to enhance accumulation of tumor suppressive proteins such 
as p21, p27, and p53, which interrupt the transition from G1 to the S phase of the cell 
cycle (145,146), and to reduce expression of cyclins A and D, and cyclin-dependent 
kinases (CDKs), all protein kinases with a key role in the regulation of the cell cycle 
(147,148). 
In most of the study carried out using purified isomers and tumor cell lines, compared to 
c9,t11 CLA, the t10,c12 CLA isomer appears to be more inhibitory of the genes that 
regulate cell cycle and growth. Also, increased apoptosis has been associated to 
decreased phosphorylation of Akt and ErbB3 proteins (149). t10,c12 CLA increased 
apoptosis by enhancing caspase-3 activity and p21 mRNA, but decreasing cell death 
regulator protein B-cell lymphoma 2 (bcl-2) mRNA (150,143), and by activating both 
caspases-3 and 9 (151). FAS protein and mRNA levels are over expressed in many 
carcinomas (152). It has been shown that the pharmacological inhibition of FAS 
expression/activity in cancer cells resulted in apoptosis suggesting that FAS expression 
is important for cell proliferation and cancer development (153). In estrogen receptor-
negative breast cancer cell line MDA-MB-231, treatment with 25 mM of c9,t11 CLA 
and t10,c12 CLA, co-ordinately decreased expression of FAS and its controlling 
transcription factor SREBP-1c, while in estrogen receptor-positive breast cancer MCF-7 
cells, the decrease of SREBP-1c and FAS expressions were dependant on the 
concentration of CLA used. (154). In both types of breast cancer cell lines, this 
inhibition was concurrent with an increased apoptosis in these cells.  
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1.5.4 Immune response and inflammatory cell signalling modulation.  
CLA is able to influence the modulation of the immune response, primarily by 
interfering with the production of eicosanoids. CLA has shown the property to decrease 
tissue levels of AA, the main substrate for the synthesis of PGE2. In turn this 
prostaglandin is a regulator of the cytokine TNFα, a key factor in several pathological 
conditions such as carcinogenesis (155), atherosclerosis (156), inflammation (157), and 
obesity (158). 
Many experimental studies have demonstrated the ability of CLA to inhibit COX, and 
interact with PPAR receptors, widely expressed in the cells of the immune system and 
determinants for the regulation of several genes involved in the proliferation of 
lymphocytes, monocytes and macrophages. Dietary CLA supplementation in rats 
showed a positive influence on the immune response, such as increased production of 
immunoglobulin IgA, IgG and IgM (159), increased phagocytosis, and proliferation of 
cytotoxic CD8 T and helper T lymphocytes (160).  
Synthetic and natural sources of CLA isomers may exert beneficial effects in many 
inflammatory diseases including colitis, atherosclerosis, metabolic syndrome and 
rheumatoid arthritis. 
In bone marrow derived dendritic cells (BMDC) stimulated with lipopolysaccharide 
(LPS), c9,t11 CLA reduced IL-12p70 and IL-12p40 while increased concentrations of 
IL-10 and surface expression of the IL-10 receptor (161). c9,t11 CLA also reduced NF-
kB signalling proteins (161-163), and TNFα production and mRNA expression in pigs 
fed with CLA after LPS treatment (164).  
In a study conducted in an animal model of inflammatory bowel disease (IBD) (165), 
CLA-fed mice were protected from weight loss, rectal bleeding, and colonic tissue 
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damage inducted by colitis, by up regulation of PPARγ and PPARδ, and a subsequent 
reduction of  inflammation mediated by NF-kB. High fat diet enriched in c9,t11 CLA 
significantly reduced the insulin resistance indicators fasting plasma glucose, insulin 
and TAG concentrations in obese mice, compared to LA enriched diet (166). This study 
showed as c9,t11 CLA increased insulin regulated glucose transporter GLUT-4 and 
IRS-1, reduced macrophage infiltration into the adipose tissue of mice, and decreased 
mRNA expression of the pro-inflammatory molecules monocyte chemoattractant 
protein 1 (MCP-1), CD68, IL-6 and TNFα in adipose tissue. All these experimental 
evidences demonstrate that c9,t11 CLA promotes insulin sensitivity by reducing adipose 
tissue inflammation. In contrast, many studies clearly highlighted the activity of t10,c12 
CLA in inducing liver steatosis and insulin resistance (167,168).  
Only few studies evaluated the effects of CLA isomers on inflammation in humans. 
Riserus et al. (168) showed that 3 months supplementation with t10,c12 CLA isomer in 
obese men decreased insulin sensitivity, increased pro-insulin, lipid peroxidation, C-
reactive protein, and fasting glucose. An analogue study, reported that c9,t11 CLA 
supplementation over 3 month in obese men (169) decreased insulin sensitivity, but in a 
less intense manner than t10,c12 CLA isomer did. Supplementation with mixtures of 
CLA isomers did not improve markers of insulin resistance in risk prone patients and 
showed inconsistent effects on healthy volunteers (170,171). 
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1.6 The endocannabinoid system (ECS) 
The endocannabinoid system (ECS) refers to the cannabinoid receptors 1 (CB1) and 2 
(CB2), and their specific endogenous ligands, a group of neuromodulatory which are 
involved in a variety of physiological processes.  
These ligands for cannabinoid receptors are also called endocannabinoids, and the best 
characterized are 2-arachidonoyl-glycerol (2-AG), and N-arachidonoylethanolamine 
(AEA or anandamide). The endocannabinoids are synthesized from AA (172), and 
modulate energy balance, feeding behavior, glucose homeostasis, hepatic lipogenesis, 
pain sensation, mood, and memory.  
The name of this system is derived from the discovery of the terpenoid derivative ∆ 9-
tetrahydrocannabinol (∆ 9-THC), the major psychoactive component of Cannabis sativa 
and marijuana (173). The milestones in the history of ECS research that led to today's 
knowledge may be briefly summarized in Fig. 4. 
CB1 are located in several areas of the brain and in a variety of tissues such as adipose 
tissue, liver, muscle, the gastrointestinal tract, pancreas, gonad and sensory neurons 
(174-181). CB2 receptors are located in immune cells such as T and B-cells, monocytes, 
and also in spleen and tonsils (182,183).  
Unlike classical neurotransmitters, endocannabinoids are not stored within the synaptic 
vesicle in cells; rather, they are synthesized on demand from phospholipid-derived 
precursors  in the cell membrane. The biosynthesis of the long chain N-
acylethanolamine (NAE) compound AEA starts with the transfer of AA from the sn-1 
position of PLs to the nitrogen atom of phosphatidylethanolamine by the acyl-
transferase Ca2+-dependent enzyme (184,185). This trans-acylase-catalyzed reaction 
leads to the formation of N-arachidonoyl-phosphatidylethanolamine (NArPE), which is  
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2600BC  The Chinese emperor Huangdi advised taking Cannabis sativa  for the 
              relief of cramps, and rheumatic and menstrual pain
1839       Publication by physician O’Shaughnessy who publicized therapeutic potential 
              of Cannabis sativa to Western world
1964       Isolation of TETRAHYDROCANNABINOL (THC), the main psychoactive 
              constituent of Cannabis sativa
1988       First identification of cannabinoid receptors in rat brain
1990       Cloning of the first G protein-coupled cannabinoid receptor CB1 in rat
1991       Cloning of the human CB1 receptor
1992       Discovery of anandamide, the first endogenous cannabinoid
1993       Cloning of the CB2 receptor
1994       Characterization of the first CB1 receptor inhibitor, SR141716 (rimonabant).
1995       The term of “Endocannabinoid ” was coined
1995       Isolation of a second endocannabinoid, 2-AG
2000s     Wide tissue distribution of CB1 receptors; 
              Characterization of peripheral endocannabinoid system (ECS); 
              Role of ECS in human obesity and obesity-related metabolic disorders
 
Figure 4. Timeline of endocannabinoid system (ECS) discoveries. 
 
subsequently hydrolyzed at the phosphoester bond site by the NAPE-specific 
‘‘phospholipase D’’ (NAPE-PLD) (186). Diacylglycerols (DAGs) derived from the 
hydrolysis of phosphatidylinositol or phosphatidic acid (187) and containing AA 
esterified in sn-2 position, represent the main precursor for 2-AG biosynthesis. 
The specific enzyme responsible for 2-AG biosynthesis in cells and tissues is named 
DAG lipase (188), and  its activity is stimulated by Ca2+ and glutathione, and selectively 
inhibited by two agents, RHC80267 and tetrahydrolipstatin (189). Two separate genes 
encode for the two DAG lipases, termed DGLα and DGLβ (188). They share around 
30% of sequence identity and aren’t specific for any of the acyl groups in sn-1 and sn-2 
position of DAGs. The endocannabinoids are synthesized and released in response to 
physiologic (neuronal depolarization) and pathologic stimuli which trigger the opening 
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of calcium channels. After their biosynthesis, these lipophilic compounds are 
immediately released and diffuse freely across cell membranes spilling out into the 
synaptic cleft where they act locally (190). The transport mechanism is currently 
unknown. Endocannabinoids then bind to and activate CB1 receptors located 
presynaptically. This reverse path is referred to as retrograde signaling. After binding to 
the CB1 and CB2 receptors the G-proteins are stimulated to relay the signals to regulate 
a number of cellular processes. Various different signaling pathways are affected by this 
G protein stimulation. CB1 but not CB2 receptor stimulation of G-proteins is directly 
coupled to inhibition of voltage-activated Ca2+ channels. Inhibition of Ca2+ channels and 
stimulation of K+ channels both inhibit neurotransmitter release. Follows the inhibition 
of adenylate cyclase (AC) with corresponding inactivation of the protein kinase A 
(PKA) phosphorylation pathway. This determines the stimulation of mitogen-activated 
protein kinase (MAPK). These two intracellular events lead to, among other effects, the 
regulation of expression of several genes.  
After endocannabinoids act locally at the site of synthesis, they are immediately 
metabolized by reuptake and subsequent hydrolysis into cells by the enzyme fatty acid 
amide hydrolase (FAAH), which predominantly catabolises AEA and 2-AG to AA and 
ethanolamine or glycerol, respectively (191,192). 2-AG can also be inactivated by the 
monoacyl-glycerol lipase (MAGL) (193), a cytosolic enzyme which is associated to the 
plasma membrane. In brain most of the 2-AG (around 85%) is hydrolyzed by MAGL 
while the remaining part is catalyzed by two enzymes, named ABHD6 and ABHD12 
(194), and this estimation has been confirmed by the selective MAGL inhibitor JZL184 
(195). The degradation of AEA and 2-AG generates AA, ethanolamine and glycerol, all 
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precursors available into the membrane PLs for a new round of endocannabinoid 
biosynthesis (196).  
Other molecules belonging to the NAEs family have been identified. The naturally 
occurring amide of PA and ethanolamine, N-palmitoylethanolamide (PEA), and the 
amide of OA and ethanolamine, N-oleoylethanolamide (OEA). These represent the most 
important congeners or endocannabinoid related compounds (ERC) that act mainly by 
influencing AEA metabolism and binding the PPARα (197,198). 
PEA and OEA have practically no effect on classical CB1 and CB2, but exert their 
biological actions targeting other types of receptors. It has been observed that topic 
application on mouse skin with PEA, this NAE-derived amide exerts anti-inflammatory 
action by direct activation of PPARα and stimulating PPARα gene expression (199). 
These effects were replicated by treatment with the synthetic PPARα agonists GW7647 
and Wy-14643 (199). Other mechanisms for the anti-inflammatory activity of PEA have 
been reported, such as enhancement of AEA actions at CB1, transient receptor potential 
of vanilloid type-1 (TRPV1) and PPARγ receptors (200). 
Conversely to AEA, OEA decreases food intake and body weight gain (201) by binding 
and increasing the transcriptional activity of PPARα (202). In wild-type mice, OEA 
stimulated lipolysis and fatty acid oxidation, but not in mutant mice deficient in PPARα 
(203). The anorectic properties of OEA were confirmed after sub-chronic treatment in 
diet-induced obese rats and wild-type mice, where OEA reduced body weight gain and 
TAG content in liver and adipose tissue, but  not in obese PPARα–/– mice (203). Other 
implications have been observed for PPARα mediated responses of OEA. These include 
neuromodulatory properties (204), and memory consolidation through noradrenergic 
activation of the basolateral complex of the amygdala (205). 
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1.7 Role of ECS in feeding behavior and energy homeostasis 
It has been well known for a long time that exposure to cannabis produces an increase 
of appetite (a phenomenon referred to as the 'munchies'). Marihuana use is associated 
with increased caloric intake and weight gain (206). This observation led to an 
exploration of the role of the ECS in the regulation of feeding behavior. It has been 
shown that central stimulation of the CB1 receptor by AEA (207) and 2-AG (208) 
increases food intake through increased hunger and decreased satiety. 
In the first study that demonstrated the central CB1 receptor-mediated overeating effect 
of AEA (207), all doses of AEA increased significantly food intake in pre-satiated male 
rats, and 1.0 mg/kg resulted the most potent dose. Hyperphagia induced by AEA was 
dose-dependently attenuated by the CB1 receptor inhibitor SR141716 (rimonabant). 
Similarly, injection of 2-AG into the nucleus accumbens shell of rats, stimulated 
feeding dose-dependently (208), and this effect was attenuated by rimonabant. In the 
same study, fasting increased levels of AEA and 2-AG in the limbic forebrain and 2-AG 
in the hypothalamus. Hypothalamic 2-AG level declined as animals ate. No changes 
were detected in satiated rats. If the hyperphagic actions of endocannabinoids were 
selectively blocked by rimonabant, but not by the antagonist of peripherally expressed 
CB2 receptors, SR144258, indicating that the overeating actions of AEA and 2-AG are 
mediated specifically by CB1 receptors (208,209).  
ECS has been proposed as power regulatory controller of the hedonic evaluation of 
palatable foods in central (209,210) and peripheral areas of the body (211). ECS is 
deeply involved in the motivation to eat at the level of nucleus accumbens and hunger in 
hypothalamus by orexigenic (appetite-stimulating) and anorexigenic (appetite-reducing) 
mediators (189). 
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Leptin might influence biosynthesis of AEA and 2-AG in hypothalamus, and it is 
believed that this hormone signals the nutritional status to the brain areas that control 
food intake and energy balance (212). Leptin reduces food intake at two levels; 1) by 
upregulating α-melanocyte-stimulating hormone, a neuropeptide with an anorexigenic 
action, and 2) downregulating orexigenic factors, such as neuropeptide Y. Acute 
treatment of leptin in normal rats reduced hypothalamic endocannabinoid levels; while 
genetically obese, chronically hyperphagic Zucker rats and mice express elevated, 
leptin-reversible, hypothalamic anandamide or 2-AG levels (174). Then, 
endocannabinoids in the hypothalamus through activation of CB1 receptors maintain 
food intake and take part of the neural control of appetite regulated by leptin. Plasma 
levels of leptin and endocannabinoids are inversely correlated. Leptin peripherally acts 
on taste function, and in wild-type mice selectively suppresses sweet taste responses, 
but not in leptin receptor-deficient mice (213-215).  
It has been shown that endocannabinoids act enhancing sweet taste, opposing to the 
action of leptin. Administration of AEA or 2-AG increases gustatory nerve responses to 
sweeteners in a concentration-dependent manner without affecting responses to salty, 
sour, bitter, and umami compounds (216).  
Endocannabinoids are not able to increase sweet taste responses at cellular, nerve, or 
behavioural levels in CB1 receptor knock-out mice, and are reduced in taste cells by 
CB1 receptor antagonist and not by CB2 receptor antagonist (216). Type II taste cells 
express CB1 and TAS1R3 sweet taste receptors (216), suggesting that the taste organ is 
a peripheral target of endocannabinoids. A recent study confirmed the involvement of 
the ECS with taste in normal-weight PROP supertasters and PROP non-tasters (217). 
The genetically determined ability to taste 6-n-propylthiouracil (PROP), is a property 
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that has been linked with lowered acceptance of some bitter foods, and increased energy 
intake and BMI. This study revealed as in normal weight subjects, taste sensitivity is 
associated with AEA and 2-AG plasma levels. In the hypothalamus, the ECS not only 
acts influencing appetite signalling, but it has been shown to interact with pathways 
known to be involved in the regulation of energy balance, and lipid and glucose 
metabolism (174,175). 
The peripheral action of the ECS is associated with fat accumulation in adipose tissue, 
and impaired and decreased glucose uptake in skeletal muscle (181,218). Also, CB1 
receptors present in liver, contribute to the peripheral metabolic activity of the ECS. 
High fat feeding increases expression of the CB1 receptor and hepatic AEA levels. In 
liver, dietary LA and pharmacological stimulation of CB1 receptor enhance gene 
expression of the lipogenic transcription factor SREBP-1c (180). Through induction of 
hepatic acetyl-CoA carboxylase-1 (ACC1) and FAS, leading to an increased hepatic 
accumulation of fat, which would be expected to enhance VLDL production and TAG 
flux, and to increase hepatic insulin resistance.   
Prior to any significant difference in body weight, high fat feeding leads the hepatic 
metabolic shift to fatty acid synthesis and reduced oxidation. This represents a direct 
effect of up regulation ECS-mediated on hepatic metabolism, rather than a secondary 
consequence of body weight change. In a correlated study (219), genetically modified 
mice for CB1 [CB1(-/-)] and liver CB1 receptors [LCB1(-/-)] fed with a high fat diet 
developed a reduced degree of dyslipidemia, hyperglycemia, steatosis, insulin and leptin 
resistance, compared to wild-type mice fed with the same diet. Also, LCB1(-/-) mice 
showed obesity in a similar manner to wild-type mice. These findings highlighted the 
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role of the endocannabinoids and their target receptors in the development of high fat 
diet-induced steatosis without increase of adipose tissue. 
It has been shown in mouse 3T3-F442A adipocytes that ECS takes part to adipocyte 
differentiation and lipogenesis, and causes depression of adiponectin expression in 
mature adipocytes (220,221).  
The reduced expression of adiponectin due to the overstimulation of CB1 receptors by 
high levels of 2-AG in adipocytes during hyperinsulinemia (condition typical of 
obesity), contributes to the hormonal and metabolic changes characterizing obesity 
(222). The CB1 receptor antagonist rimonabant restores in diet-induced obesity mice 
the normal expression of the adiponectin-dependent enzymes involved in lipid and 
glucose metabolism (223). However, the role of the ECS in adiponectin regulation still 
remains unclear, and some studies showed mixed results. Rimonabant treatment in rats 
(224) and human adipocytes (225) failed to influence adiponectin levels. No association 
has been reported among CB1 mRNA expression in adipose tissue, circulating CB1 
levels, and adipose tissue expression of adiponectin in lean and obese subjects (226). 
In  mature adipocytes through the secretion of leptin, levels of AEA and 2-AG were 
efficaciously reduced (220). Matias et al. (220) also revealed as the 
endocanabinoid/CB1 signalling stimulates insulin secretion in RIN-m5F rat β-cells 
(pancreatic cells), and it was overactive also in pancreas of mice with obesity induced 
by diet, and in the visceral adipose tissue of obese individuals. 
In pathological conditions characterized by  hyperglycemia, such as prediabetes, type 2 
diabetes and obesity, the ECS in β-cells instead of remain under insulin control, 
becomes dysregulated. The hyperinsulinemia might be reinforced by overstimulation of 
endocannabinoid receptors with the CB1/CB2 HU-210 agonist, triggering to permanent 
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hyperinsulinemia (220). This condition would increase the levels of endocannabinoids 
in β-cells, leading to endocannabinoid hyperactivity and increased lipogenesis in 
adipocytes, accompanied by decreased levels of adiponectin. Some studies have  
suggested the hyperactivity of the ECS in human obesity, and in genetic and diet-
induced obesity in animal models. The positive stimulation of the ECS in the brain and 
peripheral tissues drives robust physiologic and metabolic changes characteristic not 
only of obesity but also in conditions of insulin resistance and potentially diabetes (227, 
228). Comparison of lean and obese female human subjects showed that circulating 
AEA levels were positively correlated with BMI, while 2-AG with waist circumference 
(229). Also, obese subjects had both increased plasma AEA (35%) and 2-AG levels 
(52%) ana reduced FAAH activity (around 59%). This evidence further supports the 
role of the ECS in human obesity. Circulating 2-AG levels positively correlated to 
visceral adipose tissue, HDL-cholesterol, and high TAG concentrations in plasma of 
viscerally obese men (BMI around 31 kg/m2) (230). Reduction of body weight and 
waist circumference following a 1 year of lifestyle programme was accompanied by 
declined levels of 2-AG in plasma. In a similar study (231), a significant correlation 
between BMI and plasma AEA concentration was observed in human subjects with 
varying BMI. 
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1.8 Influence of dietary fats on endocannabinoids 
The endocannabinoids AEA and 2-AG are biosynthesized “on demand” from AA bound 
to the membrane PLs in position sn-1 and sn-2, respectively (232). 
Being an essential fatty acid, the tissue content of AA esterified to PLs is primarily 
influenced by the diet. Moreover, the content of the n-6 precursor of AA, LA, and the 
competition with other fatty acids such as eicosapentaenoic acid (EPA, 20:5 
c5,c8,c11,c14,c17) and DHA, contribute to affect AA concentrations in PLs (233,234). 
AEA and 2-AG levels were elevated in liver and erythrocytes along with food intake, 
feed efficiency, and adiposity in mice fed with a LA enriched diet (233). The addition of 
EPA and DHA to the highest level of LA in the diet reversed the adipogenic effect of 
LA and normalize endocannabinoid tone in mice. 
Some studies reported the positive correlation between dietary AA and AEA and 2-AG 
levels in the hypothalamic regions of piglet brain (235), and the inverse correlation 
between a prolonged intake in n-3 PUFA-enriched diet and endocannabinoids in mouse 
brain (236), as well as in small intestine and liver (237). 
After 14 weeks administration of a high-fat diet (60 % energy), levels of AEA in mouse 
liver were increased and the authors of this study (180) suggested the potential role for 
CB1 receptor activation in contributing to diet-induced obesity by increased fatty acid 
synthesis. Artmann et al. (237) compared the short-term effects of five different dietary 
fats on 2-AG and AEA concentrations, in rat brain, liver and duodenum. The five diets 
included: palm oil (rich in PA), olive oil (rich in OA), safflower oil (rich in LA), fish oil 
(FO), and a diet rich in AA. The authors also examined the amounts of the ERC, PEA 
and OEA, and the NAE compounds N-stearoylethanolamine, N-linoleoylethanolamine, 
22:5 n-3 NAE, and 22:6 n-3 NAE. After 1 week feeding, rats showed increased N-
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linoleoylethanolamine in brain, jejunum and liver by LA diet. The OA diet increased 
brain levels of AEA and OEA. OA diet also increased OEA in liver. The diet rich in AA 
elevated AEA and 2-AG in jejunum but none effect in liver was observed. FO diet 
decreased all NAE levels in liver. The AA and FO diets had no effect on NAEs, 
endocannabinoids or precursor lipids in brain. 
It has been shown that feeding mice with different high fat diets containing various 
amounts of SFAs, MUFAs, and PUFAs, increased levels of AEA or 2-AG, or both, in 
brown adipose tissue, heart, skeletal muscle and kidney (238). On the other hand, a diet 
higher in n-3 PUFA content reduced AEA and 2-AG levels. Another study reported the 
effects of dietary n-3 long chain polyunsaturated fatty acids (LCPUFAs) compared to a 
control diet containing no EPA and DHA (239). After 4 weeks of treatment, n-3 PUFA 
supplemented diets lowered liver and heart TAGs, and the peritoneal macrophage 
response to an inflammatory stimulus in Zucker rats. These effects were associated with 
reduced levels of AEA and 2-AG in the visceral adipose tissue, and of AEA in liver and 
heart, which, in turn, was associated with lower levels of AA in membrane PLs. The 
enzymatic activities of the AEA-hydrolyzing enzyme FAAH and the MAGL specific 
for 2-AG, did not differ.  
Experiments in vitro definitely confirmed as dietary fatty acids influence 
endocannabinoid biosynthesis and then might modulate the ECS (240,241). Treating 
mouse pre-adipocyte 3T3- F442A with 100 µM of different n-6 and n-3 PUFAs, Matias 
et al. (240) reported that AA strongly increased 2-AG levels; DHA decreased 2-AG; 
and no effect on 2-AG levels was observed after EPA treatment. If DHA decreased 
AEA levels, AA and EPA treatments did not. 3T3-L1 adipocytes were able to convert 
DHA and EPA into their NAE derivatives docosahexaenoyl ethanolamine (DHEA) and 
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eicosapentaenoyl ethanolamine (EPEA), respectively, in a dose-dependent response 
manner (241). DHA and EPA did not affect AEA level in the culture medium. 
The anti-inflammatory molecules DHEA and EPEA have been recently identified as 
alternative agonists of CB1 and CB2 receptors in human and mouse leukocytes 
(242,243). In human polymorphonuclear leukocytes, DHEA-derived products showed 
to be poorer activators of CB1 compared to AEA, but preferentially activate CB2 than 
AEA (242). The concentration of DHEA required to activate CB1 receptors was much 
higher, compared to AEA. It has been shown that DHEA possesses anti-inflammatory 
properties in both mouse peritoneal and RAW264.7 macrophages (244). Activation of 
CB2 receptors by n-3 PUFA derived metabolites, resulted in a reduction of 
inflammatory cytokines production in leukocytes (242), which finally could lead to a 
decreased state of chronic inflammation that may be associated with obesity.  
In a study conducted in humans, 2g/day of dietary krill oil for 4 weeks decreased 
plasma 2-AG levels in obese subjects (BMI around 30 kg/m2), and no changes were 
detected in BMI, waist circumference, glycemia and insulinemia after any of the 
treatments (245). The decrease of 2-AG was correlated to the decrease of plasma n-6/n-
3 phospholipid LCPUFAs ratio, with the reduced 2-AG biosynthesis probably caused 
by the replacement of 2-AG precursor, AA, with n-3 PUFAs contained in krill oil. Krill 
oil more efficiently than fish oil was able to reduce endocannabinoids in different 
tissues of obese Zucker rats (239) and in plasma of obese subjects (245). The effects of 
dietary krill oil on peripheral endocannabinoid overactivity were recently evaluated in 
mildly obese men (BMI of 32.3 kg/m2) by Berge et al. (246). After 12 and 24 weeks of 
dietary supplementation, 4 g/day of krill powder (34% proteins, 61.8% krill oil) reduced 
AEA levels in 59 and 84% subjects, respectively, compared to six control subjects that 
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had not taken any supplements. The treatment also produced a significant decrease in 
waist/hip ratio and visceral fat/skeletal muscle mass ratio at 24 weeks, but no change in 
body weight. DHA and EPA significantly increased with a reduction of TAG plasma 
levels. 
Only few data reported the possible effects of CLA on ECS. This group of unusual fatty 
acids has been found to be linked with changes of endocannabinoids levels in mouse 
brain. Mice fed with diets containing 3% of either LA or CLA for 4 weeks, showed 
significantly reduced amounts of 2-AG in the cerebral cortex, compared with LA 
treatment (247). CLA supplementation did not affect AEA, OEA, and PEA levels. The 
2-AG variations measured in the cerebral cortex were not detected in the hypothalamic 
region of the brain. In a recent study conducted on forty-two adult volunteers with 
diagnosed mildly hypercholesterolemia (248), Pintus et al. compared the effects of 90 
g/day consumption of a naturally enriched sheep cheese in some fatty acids and a 
control cheese, on plasma lipid and endocannabinoid profiles. In this 3 weeks cross-
over study, the enriched cheese in ALA, CLA and VA, decreased AEA levels. Plasma 
of volunteers also revealed significantly decreased LDL-cholesterol level and increased 
concentrations of CLA, VA, ALA and EPA. None of the parameters measured were 
modified by the control cheese. 
All these findings strongly support the significant role of dietary fatty acids in the 
physiological control of the ECS and their beneficial effects by reducing biosynthesis of 
endocannabinoids and their possible role in promoting metabolic syndrome.  
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2. Aims of the study 
CLA influencing different biochemical pathways determines alteration of body 
composition in experimental animal and impaired lipid accumulation in adipocytes, as 
well as a whole range of beneficial effects such as anti-inflammatory and anti-tumor 
activity. The central role in feeding behavior and energy homeostasis of the ECS and its 
lipid derived neuromodulatory molecules, point the need to investigate possible effects 
of CLA on the levels of endocannabinoids AEA and 2AG, along with their congeners 
OEA and PEA. 
The first objective of this thesis is to study the effects of CLA enriched diets on fatty 
acid metabolism, examining hepatic fatty acid profile, including total lipids, UFAs, 
SFAs, and the CLA derived metabolites in obese Zucker rats. In the same experimental 
animal, we also want to assess the influence of dietary CLA on the levels of 
endocannabinoids and congeners. Another issue was to evaluate and compare the 
influence of CLA supplementation in combination with fat from vegetable origin versus 
fat from animal origin on fatty acid deposition. 
Only few data resulting from trials in humans evaluating the effect of very high dose of 
CLA on biochemical and physiological parameters are available (27,28), and no studies 
have been conducted on the influence of endocannabinoid levels and biosynthesis.   
The other aim of the present study was then to measure total fatty acid profile, CLA  
metabolites, and endocannabinoids and congeners in subjects fed with a CLA enriched 
diet (mainly c9,t11 CLA isomer), for three weeks. The safety of a short term treatment 
with very high doses of CLA in humans has been already proved (27,28), but the 
influence on whole fatty acid metabolism and endocannabinoid synthesis represents an 
intriguing and unexplored issue to be investigated.  
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The effects of c9,t11 CLA on serum fatty acid and endocannabinoid profiles were 
compared to those generated by other two identical diets that differed only for the 
presence of OA or industrial trans fatty acids, instead of CLA. 
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3. Experimental design 
3.1 Study in animal model: fatty Zucker rats 
To start gaining insights on the effect of CLA on fatty acid metabolism and 
endocannabinoid biosynthesis, we have primarily performed this study evaluating fatty 
acid deposition and endocannabinoid levels in liver of Zucker rats supplemented with 
CLA isomers mixture in combination with fat from different dietary origins. These 
rodents represent a genetic model for research on obesity and hypertension (249), in 
particular the characteristically obese (or fatty) Zucker rat, which is a recessive trait 
(fa/fa) of the leptin receptor, determines hyperphagia resulting in visceral obesity and 
ectopic fat accumulation. Liver samples from Zucker rats were kindly provided by Prof. 
Jose´ AM Prates and his research team. All the detailed information regarding animals, 
CLA oil, and experimental diets is reported in reference n. 250 of the present thesis. 
Briefly, rodents were purchased from Harlan Interfauna Iberia (Barcelona, Spain) at 5 
weeks old. Upon arrival, animals were housed individually and maintained on a 12 h 
light:dark cycle at 22 ± 2 °C. After 1 week adaptation period, thirty-two obese male 
fa/fa Zucker rats were randomly divided into four groups with eight rats each (n = 8), 
and assigned to one of four diets containing palm oil (PO) or ovine fat (OF), 
supplemented or not with 1% of 1:1 c9,t11 and t10,c12 CLA isomers mixture, and fed 
for 13-14 weeks. The differences of the four experimental diets are reported in Table 1. 
The CLA oil purchased from PharmaNutrients Inc. (Gurnee, IL,USA) had a purity of 
80%. Peritoneal ovine fat collected from lambs raised with forage enriched in seed oils, 
was finally melted and filtered to subsequent mixture with the remaining components of 
the experimental diets (purchased from Provimi Kliba SA, Kaiseraugst, Switzerland). 
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Diets Composition
PO 11.25% of palm oil plus 3.75% of sunflower oil
POCLA 11.25% of palm oil plus 2.53% of sunflower oil and 1.22% of CLA oil
OF 11.25% of ovine fat plus 3.75% of sunflower oil
OFCLA 11.25% of ovine fat plus 2.53% of sunflower oil and 1.22% of CLA oil
 
Table 1. Fat composition of the experimental diets. 
 
Diets were prepared following the AIN-93G formulation, with some modifications to 
obtain high fat diets. Diets had a dry matter concentration of 928 g/kg feed and the 
following crude composition (g/100 g dry matter) was 20.0 proteins, 16.6 fats, 3.9 ash, 
3.9 fibers, and 55.6 carbohydrates. The four experimental diets differed in their fat 
composition. Two groups received fat from vegetable origin: group PO 11.25% of palm 
oil plus 3.75% of sunflower oil; group POCLA 11.25% of palm oil plus 2.53% of 
sunflower oil and 1.22% of CLA oil. The other two groups, OF and OFCLA, had the 
same fat composition of PO and POCLA, respectively, but received ovine fat instead of 
palm oil. Animals had free access to water and food. Body weight and food intake were 
monitored twice a week. At the end of the scheduled feeding time with experimental 
diets, rats were killed by decapitation, under light isofluorane anesthesia. Liver was 
dissected, weighed and stored at -80 °C. The experimental protocol of this study was 
reviewed by the Ethics Commission of CIISA/FMV and approved by the Animal Care 
Committee of the National Veterinary Authority of Portugal, following the appropriated 
European Union guidelines (N. 86/609/EEC).  
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3.2 Randomized cross-over study in humans 
In order to extend the study of nutritional influence of CLA on fatty acid metabolism, 
we analyzed through a lipidomic approach total lipid profile, and plasma levels of 
endocannabinoids and congeners in healthy subjects fed with a very high dose of dietary 
CLA.  
In this controlled single blind randomized multiple crossover trial with three 
consecutive periods of 21 days, the effects of CLA (mainly c9,t11 CLA isomer) were 
compared to OA and a diet rich in industrial trans fatty acids. 
Samples of human plasma were provided by Prof. Ingeborg Brouwer and Prof. Martijn 
B. Katan, Department of Health Sciences, University of Amsterdam. The approved 
protocol for this clinical trial, the characteristics of enrolled volunteers into the study, 
and the fatty acid composition of the oils and fats used to produce the experimental diets, 
can be found in a paper previously published (28). 
We screened plasma from 24 healthy men and women (aged 18 to 65) which consumed 
each of three diets for three weeks, in random order.  
Diets were identical except for 7% of total energy (in a 2500 Kcal diet, approximately 
20 g/day) which was provided either by:  
• 80% c9,t11 CLA and 20% t10,c12 CLA (CLA diet);  
• Industrial trans fatty acids (TFA diet);  
• Oleic acid (OA diet).  
 
 
 
 52
4. Material and methods 
Acetonitrile (CH3CN), methanol (CH3OH), chloroform (CHCl3), n-hexane (C6H14), 
ethanol (C2H5OH), acetic acid (CH3COOH) were HPLC grade and purchased from 
Sigma Chemicals Co., St. Louis, MO, USA. All standards of SFAs, UFAs, and c9,t11 
CLA and t10,c12 CLA isomers, were purchased from the same company. 
Ascorbic acid, potassium hydroxide (KOH), hydrochloric acid (HCl) were purchased 
from Carlo Erba, Milano, Italy.  Deferoxamine mesylate (desferal) was purchased from 
CIBA-Geigy, Basel, Switzerland. Internal deuterated standards for AEA, 2-AG, PEA 
and OEA quantification by isotope dilution ([2H]8AEA, [2H]52AG, [2H]4 PEA, [2H]4 
OEA) were purchased from Cayman Chemicals, MI, USA. 
 
4.1 Extraction of total lipids 
Total lipids were extracted by the method of Folch (251). Briefly, samples of human 
plasma (1 ml) and rat liver (about 0.3 g), were homogenized each into a 2:1 chloroform-
methanol solution containing 2 μg of vitamin E and deuterated AEA (200 ng), 2-AG 
(300 ng), OEA (200 ng), and PEA (100 ng).  
Tubes containing lipids under extraction were kept one hour in the dark, added an equal 
volume of double-distilled water (ddH2O) to that of methanol present, then left another 
hour in the dark. Samples were centrifuged for one hour at 900 x g to facilitate the 
separation of the chloroform phase from the aqueous-methanol. 
The lower chloroform phase containing lipids was collected, divided in different 
aliquots for subsequent analyses and evaporated under vacuum by a rotator evaporator 
at room temperature.  
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4.2 Quantitative determination of total lipids 
Total lipid quantification was performed by the method of Chiang (252) on evaporated 
aliquots of chloroform phase containing lipids, collected after initial lipid extraction. 
1.5 ml of the Chiang reagent (2 g of K2Cr2O7 into 4 ml ddH2O, make up to a final 
volume of 100 ml adding H2SO4) was added, and the samples incubated for 30 min. at 
100 °C. Finally, 1.5 ml of ddH2O was added, and the absorbance measured at the 
wavelength of 600 nm by a colorimeter. To determine the concentration of total lipids a 
standard curve of corn oil was used, and the range of reliability of the method was 
between 100 and 800 mg of lipids. 
 
4.3 Fatty acid analysis of tissue lipid fraction 
An aliquot of the lipid fraction for each sample was mildly saponified using a procedure 
in order to obtain FFAs for HPLC analysis. Lipid extracts were dissolved in 5 ml of 
ethanol, 100 µl of desferal (25 mg/ml ddH2O), 1 ml of a 25% solution of ascorbic acid 
in water, 0.5 ml of 10N KOH, and left 14 hours in the dark at room temperature. Later, 
10 ml of n-hexane and 7 ml of ddH2O were added, then the samples were acidified with 
0.35 ml of 37% HCI, to a pH 3-4. Samples were centrifuged for 1h at 900 x g. The 
hexane phase containing FFAs was collected, the solvent evaporated, and the residue 
was dissolved in 0.5 ml of CH3CN/0.14% of CH3COOH (v/v). 
Separation of fatty acids, including CLA and its metabolites, was carried out with an 
Agilent 1100 HPLC system (Agilent, Palo Alto, Calif., USA) equipped with a diode 
array detector. A C-18 Inertsil 5 ODS-2 Chrompack column (Chrompack International 
BV, Middleburg, The Netherlands), 5 μm particle size, 150 x 4.6 mm, was used with a 
mobile phase of CH3CN/H2O/CH3COOH (70/30/0.12, v/v/v) at a flow rate of 1.5 
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ml/min (253). Conjugated diene unsaturated fatty acids were detected at 234 nm. 
Spectra (195–315 nm) of the eluate were obtained every 1.28 s and were electronically 
stored. Second-derivate UV spectra of the conjugated diene fatty acids were generated 
using Phoenix 3D HP Chemstation software (Agilent, Palo Alto, CA). These spectra 
were acquired to confirm identification of the HPLC peaks (254). 
Since SFAs are transparent to UV, after derivatization, they were measured as fatty acid 
methyl esters (FAMEs), by a gas chromatograph (Agilent, Model 6890, Palo Alto, CA) 
equipped with split ratio of 20:1 injection port, a flame ionization detector (FID), an 
autosampler (Agilent, Model 7673), a 100 m HP-88 fused capillary column (Agilent). 
Finally, data were analyzed by the Agilent ChemStation software system. The injector 
and detector temperatures were set up at 250°C and 280°C, respectively. H2 served as 
carrier gas (1 ml/min), and the FID gases were H2 (30 ml/min), N2 (30 ml/min), and 
purified air (300 ml/min). The temperature program was as follows: initial temperature 
was 120°C, programmed at 10°C/min to 210°C and 5°C/min to 230°C, then 
programmed at 25°C/min to 250°C and held for 2 min. 
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4.4 Analysis of the endocannabinoids and their congeners 
Aliquots of organic phase (chloroform) containing extracted lipids were evaporated to 
dryness under vacuum, and reconstituted with 0.3 ml and 0.4 ml of 100% methanol for 
human plasma and rat liver samples, respectively.  
Quantification of AEA, 2-AG, PEA and OEA, was carried out by liquid 
chromatography-atmospheric pressure chemical ionization-mass spectrometry (LC-
APCI-MS), and using selected ion monitoring (SIM) at M+1 values for the four 
compounds and their deuterated homologues. A C-18 Zorbax Eclipse Plus column 
(Agilent, Palo Alto, CA) 5 µm particle size, 50 x 4.6 mm, was used with a mobile phase 
of CH3OH/H2O/CH3COOH (80/20/0.3, v/v/v) at a flow rate of 0.5 ml/min. 
 
4.5 Statistical analysis 
To calculate mean, standard deviation, and standard error of the measurements, InStat 
software (GraphPad Software, San Diego, CA, USA) was used. Statistical differences 
among different experimental dietary treatments in human plasma and rat liver 
experiments were evaluated by one-way ANOVA and the Bonferroni test for post hoc 
analyses. CLA dose response curve in human was assessed by Pearson simple 
correlation analysis. We assumed statistical significance for p-value <0.05. 
 
 
 
 
 
 
 56
5. Summary of results 
In the first part of this thesis, we aimed to evaluate the CLA activity on fatty acid 
metabolism in liver of Zucker rats with two very different background diets (Fig.5). One 
of vegetable origin, PO, characterized by high levels of PA and OA and low in ALA, 
while the other one, OF, characterized by high levels of trans fatty acids and RA. The 
fatty acid characterization of the four experimental diets is presented in Table 2. 
 
 
 
 
Figure 5. Background of vegetable (PO) and animal origin (OF) diets. 
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PO POCLA OF OFCLA
Fatty acids
 12:0 0.020 0.019 0.011 0.011
 14:0 0.113 0.105 0.162 0.169
 15:0 0.006 0.006 0.038 0.040
 16:0 4.354 3.938 1.512 1.550
 c7-16:1 0.004 0.003 0.029 0.030
 c9-16:1 0.025 0.015 0.068 0.073
 c9-17:1 0.004 0.002 0.018 0.016
 18:0 0.520 0.428 2.520 2.709
 c9-18:1 4.293 3.392 2.676 2.646
 18:2n-6 2.460 1.680 1.884 1.537
 18:3n-3 0.016 0.012 0.148 0.156
 20:0 0.042 0.033 0.026 0.028
 20:2n-6 0.001 n.d. 0.002 0.004
 22:0 0.027 0.016 0.023 0.019
 24:0 0.020 0.013 0.012 0.010
 18:1 isomers
 t6 + t7 + t8 0.009 0.007 0.072 0.077
 t9 0.011 0.009 0.061 0.067
 t10 0.011 0.008 0.113 0.105
 t11 0.007 0.006 1.106 1.187
 t12 n.d. n.d. 0.128 0.142
 c11 0.173 0.117 0.131 0.132
 c12 0.017 0.004 0.136 0.149
 c13 0.002 0.003 0.019 0.018
 t16 + c14 0.002 0.001 0.053 0.057
 c15 n.d. n.d. 0.023 0.024
Non-conjugated 18:2 isomers
 t9,t12 n.d. n.d. 0.053 0.059
 t8,c12/c9,t12 n.d. n.d. 0.035 0.052
 t8,c13/c9,t13 0.047 0.038 0.022 0.023
 t9,c12 0.044 0.037 0.016 0.018
 t11,c15 n.d. n.d. 0.191 0.204
 c9,c15 n.d. n.d. 0.022 0.024
 c12,c15 n.d. n.d. 0.017 0.018
 Conjugated (CLAs)
 t12,t14 n.d. n.d.  <0.001 0.005
 t11,t13 n.d. n.d. 0.013 0.015
 t10,t12 0.002 0.008 0.004 0.011
 t9,t11 0.002 0.008 0.008 0.016
 t8,t10  <0.001 0.005 0.001 0.001
 t7,t9  <0.001  <0.001 0.001 0.001
 c/t11,13 0.001 n.d. 0.049 0.058
 t10,c12 n.d. 0.260 n.d. 0.270
 c9,t11 0.002 0.268 0.149 0.430
 t8,c10  <0.001 0.003 0.004 0.006
 t7,c9  <0.001  <0.001 0.005 0.006
   n.d.= not detected
 
Table 2. Fatty acid composition (g/100 g diet) of experimental diets. 
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5.1 Modulation of body composition and fat deposition in liver of 
Zucker rats by dietary CLA.  
CLA feeding for 3 months decreased body and liver weight irrespective of the 
background lipid diets (Fig.6). Data about body composition variables were previously 
published by Martins SV et al. (255). The decrease of liver weight was mainly due to a 
reduced deposition of lipids (Fig.7). 
Significance level
Growth and body composition PO POCLA OF OFCLA SEM CLA Fat CLA x Fat
Initial body weight (g) 240.0 234.0 234.0 234.0 11.2 NS NS NS
Final body weight (g) 577.0 552.0 584.0 511.0 12.7 *** NS NS
Daily feed intake (g/d) 23.7 23.0 23.9 21.0 0.5 ** NS NS
Retroperitoneal fat weight (g) 24.0 24.7 23.7 20.7 1.6 NS NS NS
Epididymal fat weight (g) 13.7 15.2 14.7 14.6 0.6 NS NS NS
Liver weight (g) 62.2 54.7 60.6 48.1 1.9 *** * NS
 
 
Figure 6. Body composition variables. 
Dietary treatments: PO, palm oil diet; POCLA, palm oil diet + 1 % of conjugated linoleic acid; OF, 
ovine fat diet; OFCLA, ovine fat diet + 1 % of conjugated linoleic acid. Mean values were significant: NS 
P>0.05, * P<0.05, ** P<0.01, *** P<0.001. 
 
 
 
Figure 7. Lipid deposition in liver. 
Dietary treatments: PO, palm oil diet; POCLA, palm oil diet + 1 % of conjugated linoleic acid; OF, 
ovine fat diet; OFCLA, ovine fat diet + 1 % of conjugated linoleic acid. Statistical significance: p-value 
<0.05. 
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5.2 Modulation of liver fatty acid profile by dietary CLA in Zucker 
rats.  
CLA intake modified AA (20:4) concentration with a slight increase of about 15% with 
both palm oil (POCLA) or ovine fat (OFCLA) diets (Fig.8). While DHA (22:6) 
increased (about 25%) when CLA was included in the OF diet (OFCLA), compared to 
PO diet enriched in CLA (Fig.9). DHA increase resulted in a higher n-3 highly 
unsaturated fatty acid (HUFA) score (Fig.10). ∆9 desaturase index (or ∆9 desaturase 
activity) decreases with CLA intake with both diets (Fig.11). Interestingly, only in the 
OF diets, the increase in n-3 HUFA score was inversely correlated to ∆9 desaturase 
index (Fig.12).  
As expected, CLA levels were higher after CLA feeding, but also with OF diet not 
supplemented in CLA which, containing RA, increased CLA liver content with respect 
to both PO and POCLA diets (Fig.13). 
 
 
 
Figure 8. Main n-6 PUFAs. 
Dietary treatments: PO, palm oil diet; POCLA, palm oil diet + 1 % of conjugated linoleic acid; OF, 
ovine fat diet; OFCLA, ovine fat diet + 1 % of conjugated linoleic acid. Statistical significance: p-value 
<0.05. 
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Figure 9. Main n-3 PUFAs. 
Dietary treatments: PO, palm oil diet; POCLA, palm oil diet + 1 % of conjugated linoleic acid; OF, 
ovine fat diet; OFCLA, ovine fat diet + 1 % of conjugated linoleic acid. Statistical significance: p-value 
<0.05. 
 
 
 
 
 
Figure 10. n-3 HUFA score, DHA/EPA and DHA/ALA ratios. 
Dietary treatments: PO, palm oil diet; POCLA, palm oil diet + 1 % of conjugated linoleic acid; OF, 
ovine fat diet; OFCLA, ovine fat diet + 1 % of conjugated linoleic acid. Statistical significance: p-value 
<0.05. n-3 HUFA score was calculated by the ratio 20:5n-3+22:6n-3/20:5n-3+22:6n-3+ 
20:4n-6+22:5+20:3n-6+20:3n-9+22:4n-6. 
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Figure 11. ∆9 desaturase activity. 
Dietary treatments: PO, palm oil diet; POCLA, palm oil diet + 1 % of conjugated linoleic acid; OF, 
ovine fat diet; OFCLA, ovine fat diet + 1 % of conjugated linoleic acid. Statistical significance: p-value 
<0.05. ∆9 desaturase activity was calculated by the 16:1+18:1/16:0 + 18:0 ratio. 16:1, palmitoleic acid; 
18:1, oleic acid; 16:0, palmitic acid; 18:0, stearic acid. 
 
 
 
Figure 12. Correlation between n-3 HUFA score and ∆9 desaturase 
index in OF diets with or without CLA supplementation. 
∆9 desaturase activity was calculated by the 16:1+18:1/16:0 + 18:0 ratio. 16:1, palmitoleic acid; 18:1, 
oleic acid; 16:0, palmitic acid; 18:0, stearic acid. 
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Figure 13. Cis9,trans11 and trans10,cis12 CLA amounts. 
Dietary treatments: PO, palm oil diet; POCLA, palm oil diet + 1 % of conjugated linoleic acid; OF, 
ovine fat diet; OFCLA, ovine fat diet + 1 % of conjugated linoleic acid. Statistical significance: p-value 
<0.05. 
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5.3 Modulation of liver retinol concentration by dietary CLA in 
Zucker rats. 
CLA feeding increased retinol level, but was significantly only versus PO diet (Fig.14). 
 
 
 
 
 
Figure 14. Retinol concentration in liver of Zucker rats. 
Dietary treatments: PO, palm oil diet; POCLA, palm oil diet + 1 % of conjugated linoleic acid; OF, 
ovine fat diet; OFCLA, ovine fat diet + 1 % of conjugated linoleic acid. Statistical significance: p-value 
<0.05. 
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5.4 Influence of dietary CLA on endocannabinoid levels in Zucker rat 
liver. 
The results of the experiments show as CLA does not alter the levels of 
endocannabinoids in the liver of Zucker rats. We found only a non-statistical significant 
decrease in the levels of AEA in the OF diet, compared with the same enriched in 1% 
CLA. The most interesting result for those anorectic properties ascribed to OEA comes 
out by  the CLA action on the levels of this NAE compound, even in the presence of 
different background diets. CLA feeding significantly enhances OEA levels in both 
diets POCLA and OFCLA (Fig.15).  
Interestingly, despite the PO diet is rich in OA (Table 2), the intake of CLA increases 
the levels of OEA. We also found between the two dietary treatments based on ovine fat, 
a statistically significant increase of PEA in favor of the OFCLA diet. 
 
 
 
Figure 15. OEA concentration in liver of Zucker rats. 
Dietary treatments: PO, palm oil diet; POCLA, palm oil diet + 1 % of conjugated linoleic acid; OF, 
ovine fat diet; OFCLA, ovine fat diet + 1 % of conjugated linoleic acid. Statistical significance: p-value 
<0.05. 
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5.5 Modulation of polyunsaturated fatty acids (PUFAs) and CLA 
metabolism by very high dose of dietary CLA in human plasma. 
After having evaluated the effects of dietary CLA on fatty acid metabolism and 
endocannabinoid levels in the liver of Zucker rats, we analyzed plasma samples from 
volunteers who have had taken very high doses of dietary CLA, and compared its 
effects on lipid metabolism with a diet enriched in trans fatty acids of industrial origin, 
and a control diet characterized by the presence of OA. TFA and CLA diets increased 
serum total lipids relative to OA control diet (Fig.16).  
Calculating the percentage of the produced  ALA metabolites (fatty acids belonging to 
the n-3 family) with respect to their ALA precursor for the three different diets, CLA 
and trans fatty acids are more efficient than OA in reducing metabolism/incorporation 
of ALA metabolites (Fig.17).  
With regard to the n-6 fatty acids, CLA compared to OA significantly decreases the 
metabolism and the incorporation of the LA metabolites (Fig.18). CLA competes with 
LA for the ∆6 desaturase. Besides, TFA compared to the OA diet, significantly 
decreased metabolism/incorporation of LA metabolites.  
Regarding the n-9 fatty acids family, compared to OA diet, TFA decreases in a 
significant manner the metabolism/incorporation of the OA metabolites, while CLA diet 
doesn’t (Fig.19). Considering the metabolic influence of the CLA dietary treatment only, 
CLA is desaturated and elongated less than LA but more than OA, and competes with 
LA for metabolism/incorporation of metabolites (Fig.20). CLA increased serum level of 
ALA (Fig.21) and LA (Fig.22), and reduced that of AA (Fig.22), relative to OA control 
diet. We can conclude that compared to both TFA and OA diets, CLA significantly 
reduces n-6 HUFAs (Fig.23), which resulted in an increased n-3 HUFA score (Fig.24).  
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Figure 16. Total lipids in human plasma. 
Dietary treatments: CLA diet, 80% c9,t11 CLA and 20% t10,c12 CLA; TFA diet, industrial trans fatty 
acids; OA diet, oleic acid. Statistical significance: p-value <0.05.  
 
 
 
 
 
 
Figure 17. Alpha linolenic acid (ALA) metabolism. 
ALA metabolism was calculated as (18:4+EPA+DHA)*100/ALA. Dietary treatments: CLA diet, 80% 
c9,t11 CLA and 20% t10,c12 CLA; TFA diet, industrial trans fatty acids; OA diet, oleic acid. Statistical 
significance: p-value <0.05 
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Figure 18. Linoleic acid (LA) metabolism. 
LA metabolism was calculated as (22:5+22:4+AA+20:3n-6+GLA)*100/ LA. Dietary treatments: CLA 
diet, 80% c9,t11 CLA and 20% t10,c12 CLA; TFA diet, industrial trans fatty acids; OA diet, oleic acid. 
Statistical significance: p-value <0.05. 
 
 
 
 
 
 
 
 
Figure 19. Oleic acid (OA) metabolism. 
OA metabolism was calculated as 20:3n-9*100/OA. Dietary treatments: CLA diet, 80% c9,t11 CLA and 
20% t10,c12 CLA; TFA diet, industrial trans fatty acids; OA diet, oleic acid. Statistical significance: p-
value <0.05. 
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Figure 20. Effect of CLA diet on conjugated linoleic acid (CLA), linoleic 
acid (LA), and oleic acid (OA) metabolism in human plasma. 
CLA metabolism was calculated as (CD 20:4+CD 20:3+CD 18:3+CD 16:2)*100/CLA; LA metabolism 
was calculated as (22:5+22:4+AA+20:3n-6+GLA)*100/ LA; OA metabolism was calculated as 20:3n-
9*100/OA. Statistical significance: p-value <0.05. 
 
 
 
 
 
 
 
 
 
Figure 21. Main n-3 PUFAs. 
Dietary treatments: CLA diet, 80% c9,t11 CLA and 20% t10,c12 CLA; TFA diet, industrial trans fatty 
acids; OA diet, oleic acid. Statistical significance: p-value <0.05. 
 69
 
 
Figure 22. Main n-6 PUFAs. 
Dietary treatments: CLA diet, 80% c9,t11 CLA and 20% t10,c12 CLA; TFA diet, industrial trans fatty 
acids; OA diet, oleic acid. Statistical significance: p-value <0.05. 
 
 
 
 
 
 
 
 
 
Figure 23. n-6 HUFAs. 
Dietary treatments: CLA diet, 80% c9,t11 CLA and 20% t10,c12 CLA; TFA diet, industrial trans fatty 
acids; OA diet, oleic acid. Statistical significance: p-value <0.05. n-6 HUFAs refers to the sum of 20:3n-
6, 20:4n-6, and 22:5n-6. 
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Figure 24. n-3 HUFA score. 
Dietary treatments: CLA diet, 80% c9,t11 CLA and 20% t10,c12 CLA; TFA diet, industrial trans fatty 
acids; OA diet, oleic acid. Statistical significance: p-value <0.05. n-3 HUFA score was calculated by the 
ratio 20:5n-3+22:6n-3/20:5n-3+22:6n-3+20:4n-6+22:5+20:3n-6+20:3n-9+22:4n-6. 
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As might be expected, the amount of CLA and its metabolic derivatives are much 
greater in subjects who took high doses of CLA, compared to the other dietary 
treatments, TFA and OA. The desaturation-elongation index has been used to estimate 
the degree of metabolization of CLA into its diene conjugated metabolites. This index is 
given by the  ratio of the metabolic derivatives of CLA (CD 16:2, CD 18:3, CD 20:3, 
CD 20:4) and CLA itself. CLA diet compared to OA shows less efficient conversion of 
CLA into its CD metabolites through saturation of enzymatic active sites (Fig.25). Also, 
the index of peroxisomal β-oxidation, given by the ratio between CD 16:2 and CLA, is 
significantly lower for the individuals who have taken high doses of CLA, compared to 
TFA and OA dietary treatments (not differences have been observed between them).  
 
 
 
 
Figure 25. CLA metabolism in human plasma. 
CLA metabolism was calculated as (CD 20:4+CD 20:3+CD 18:3+CD 16:2)*100/CLA. Dietary 
treatments: CLA diet, 80% c9,t11 CLA and 20% t10,c12 CLA; TFA diet, industrial trans fatty acids; OA 
diet, oleic acid. Statistical significance: p-value <0.05. 
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5.6 Effect of very high dose of dietary CLA on saturated fatty acids 
(SFAs) metabolism. 
With regard to the measurement of serum SFA levels in samples from subjects who 
took the three different diets, an interesting result comes out from the calculation of the 
22:0/20:0 fatty acids ratio, an index of fatty acid elongation. In fact, high dose of dietary 
CLA significantly decreases the 22:0/20:0 ratio, compared to OA control diet (Fig.26). 
The fatty acid elongation index in the TFA dietary treatment is intermediate to those 
calculated for the other two diets. 
In terms of total amount of SFAs per ml of plasma, only OA and TFA showed statistical 
difference, and the values obtained were of 3.47, 3.67, and 3.91 µmoles/ml for OA, 
CLA, and TFA diets, respectively.  
 
 
 
 
 
Figure 26. 22:0/20:0 ratio. 
Dietary treatments: CLA diet, 80% c9,t11 CLA and 20% t10,c12 CLA; TFA diet, industrial trans fatty 
acids; OA diet, oleic acid. Statistical significance: p-value <0.05. 
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5.7 Modulation of retinol concentration by very high dose of dietary 
CLA in human plasma. 
CLA compared to TFA and OA diets doesn’t modify significantly total retinol level in 
human plasma (Fig.27). Only the difference found between TFA and OA dietary 
treatments was statistically significant. 
 
 
 
 
 
 
 
Figure 27. Retinol concentration in human plasma. 
Dietary treatments: CLA diet, 80% c9,t11 CLA and 20% t10,c12 CLA; TFA diet, industrial trans fatty 
acids; OA diet, oleic acid. Statistical significance: p-value <0.05. 
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5.8 CLA dose-response curve in human plasma. 
The result of a dose-response curve for CLA in humans is presented in Fig.28. The 
curve was made by measuring the amount of CLA in plasma following administration 
of specific quantities of CLA by a number of individuals (N) belonging to five different 
groups (0, 1, 2, 3, and 20). Administered CLA was 0, 1, 2, 3, and 20 g per day, 
respectively, while CLA plasma levels are reported in the y-axis of the Cartesian 
coordinate system, and expressed as nmols/ml plasma. The relationship of 
proportionality expressed by the linear curve is valid until the amount of 20 g of CLA 
taken daily by volunteers.  
 
 
 
Descriptive Statistics
Group Mean Std Dev Std Err N
0 16.322 7.444 2.245 11
1 52.716 22.843 7.614 9
2 98.152 20.364 7.200 8
3 183.434 79.211 26.404 9
20 512.748 170.442 85.221 4
 
 
Figure 28. CLA dose-response curve in human plasma. 
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5.9 Influence on endocannabinoid levels by very high dose of dietary 
CLA in human plasma. 
Results from the randomized cross-over study conducted in humans on the influence of 
CLA on endocannabinoids and their congeners are presented in Fig.29 and Fig.30, 
respectively. High dose of CLA, does not cause significant changes in the concentration 
of AEA, and instead slightly increases 2-AG level (Fig.29). Even not statistically 
significant, we note that high doses of CLA raised plasma concentrations of OEA and 
PEA (Fig.30), compared to the OA control diet. No particular influence has been 
observed about the dietary treatment with industrial trans fatty acids. 
 
 
 
 
Figure 29. Levels of endocannabinoids in human plasma. 
Dietary treatments: CLA diet, 80% c9,t11 CLA and 20% t10,c12 CLA; TFA diet, industrial trans fatty 
acids; OA diet, oleic acid. Statistical significance: p-value <0.05. 
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Figure 30. PEA and OEA concentrations in human plasma. 
Dietary treatments: CLA diet, 80% c9,t11 CLA and 20% t10,c12 CLA; TFA diet, industrial trans fatty 
acids; OA diet, oleic acid. Statistical significance: p-value <0.05. 
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6. Discussion 
6.1 Effect of dietary CLA on fatty acid metabolism. 
The aim of the present work was to evaluate the effects of dietary CLA on fatty acid 
metabolism, tissue fatty acid incorporation and endocannabinoid biosynthesis in an 
experimental model of obesity and in healthy volunteers. The study carried out in liver 
of obese Zucker rats, compared the effect of an equimolar mix of c9,t11 and t10,c12 
CLA isomers (about 1%) with two different background diets, one based on fat of 
vegetal origin, PO, and the other made with a fat content of animal origin, OF. 
Treatment lasted 3 months.  
We found reduced lipid deposition in liver and decrease of body weight with both 
dietary treatments supplemented with CLA, as shown in previous studies (250), more 
evident with OF background diet. Retroperitoneal fat also decreased, even though not 
significantly, only in rats treated with CLA and OF diet. Interestingly, if we calculate 
the ratio between the two fat compartments retroperitoneal and epididymal, which 
respectively represent the visceral and the subcutaneous fats, there is a clear effect of 
OF diet (1.6 vs. 1.4). This data, even though not significant, merits further studies to 
evaluate the capacity of CLA with different background diet to modify adipose tissue 
compartmentalization probably by influencing insulin sensitivity and/or PPARγ activity. 
This effect may be mediated by the changes in PUFA metabolism exerted differently by 
CLA feeding according to background diet. In fact, even though rats fed both diets 
POCLA and OFCLA showed increased concentration of AA, which confirms previous 
data in the literature (250), only with OFCLA diet, liver of Zucker rats had elevated 
levels of DHA which results in a higher n-3 HUFA score. Interestingly, it has been 
shown that dietary n-3 PUFAs ameliorate insulin resistance (256) and enhanced PPARγ 
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activity (257). Therefore, the trend to improve adipose tissue compartmentalization in 
rats fed CLA with OF diets may be due to the improved n-3 HUFA score.  
It has been shown that dietary intake of CLA modulates SFAs, particularly PA and SA, 
as well as MUFA palmitoleic acid and OA (258). In the present study, we found a 
reduced ∆9 desaturase index in the liver, after feeding CLA in combination with OF 
diet, and in a lesser extent with PO diet. Interestingly, in rats fed OF diets this index was 
strongly correlated to n-3 HUFA score, suggesting that n-3 PUFAs may downregulate 
SREBP-1 activity and thereby decreasing TAG biosynthesis, as already shown in 
different experimental models (257). In fact, fat deposition in the liver is reduced 
significantly by dietary CLA, more pronounced with OF diet. 
Retinoids (vitamin A and its analogs) play an essential role in mammals for maintaining 
health and are involved in many physiological functions (259) including vision (260), 
regulation of cell proliferation and differentiation (261), immune function (262), and 
growth of bone tissue (263). Mammals obtain vitamin A in the form of retinyl esters 
and retinol (from animal products), or as provitamin A carotenoids such as β-carotene 
(from vegetables and fruits). It is demonstrated the capacity of CLA to alter the 
metabolism of retinoids in rats (264) and mice (265). In particular, it has been shown 
that chronic intake of CLA in rodents influences the maintenance of serum, liver, and 
adipose retinoid metabolism (265). t10,c12 and CLA c9,t11 CLA isomers enhance 
uptake of dietary vitamin A in liver and its resecretion into the bloodstream in the form 
of retinol bound to retinol binding protein (RBP) (265). Experimental data in mice have 
led to hypothesize that CLA might also increase the absorption of dietary vitamin A 
(266). Our data confirmed that dietary CLA intake increases retinol level in liver of 
Zucker rats, but the increase is significant only when CLA was in combination with PO 
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diet and not with OF diet. It might be possible that the marginal increase by feeding 
CLA with OF diet is due to a higher secretion of retinol bound to RBP to serum. 
Unfortunately, we don’t have data on circulating retinol and/or RBP levels, however, 
we may speculate that OF by increasing n-3 PUFA levels, in combination with CLA 
may induce liver PPARα which increases RBP protein expression (267) and favor the 
exportation of retinol from liver to the blood. More specific studies are needed to 
unravel this important issue, which may explain some of the effects of CLA in 
particular as anti-carcinogenic activity (113-115). In fact, CLA and retinol share 
biological activities on suppressing mammary gland development (117), inhibit terminal 
duct and alveolar cell proliferation (117) and block mammary tumorigenesis induced by 
carcinogens (116,118). 
We also evaluated the effects of very high dose of CLA in humans, measuring lipid 
profile in plasma of healthy subjects who consumed each three distinct diets for three 
weeks. The daily dietary treatments consisted in supplementation with 20g of CLA 
isomers (80% c9,t11 and 20% t10,c12), or industrial trans fatty acids, or OA. Using the 
dose-response curve of CLA intake in humans previously published (268), we found 
that  daily intake of 20g CLA fits in the curve showing proportionality up to 20g/d. 
Since both CLA and LA are likely to share the same enzyme system for chain 
desaturation and elongation, increasing CLA intake may interfere with the further 
metabolism of LA. Fatty acid analysis of total lipids showed that CLA decreases the 
metabolism and the incorporation of LA metabolites. High dose of dietary CLA 
increases plasma levels of LA, compared to OA diet, while LA metabolites (including 
GLA, n-6 20:3, and AA) were significantly reduced. Of particular interest is the 
consistent drop in AA, which is the substrate for the COX and LOX pathways of 
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eicosanoid biosynthesis. Thus the CLA effect on AA suppression might represent a 
crucial mechanism for beneficial actions of CLA on human health and protection 
against some pathological conditions (33). We found that CLA also influence ALA 
metabolism and increased n-3 HUFA score, but this effect may be a consequence of the 
action of CLA in decreasing n-6 HUFAs.   
Also, we confirmed the effect of CLA in reducing elongation of long chain fatty acids 
(LCFAs), another beneficial property that can be exploited in addition to a specific 
mixture of TAGs, the so called Lorenzo's oil, for the treatment of metabolic disease 
such as adrenoleukodystrophy (ALD) (269). This is a rare metabolic disease, 
transmitted through the maternal X chromosome to male children (270). This metabolic 
deficiency prevents the very long chain fatty acids (VLCFAs) to undergo the process of 
β-oxidation in the peroxisomes, resulting in their accumulation in plasma and tissues. 
High levels of VLCFAs may impair myelin biosynthesis, with the loss of neuronal 
function in different brain areas.. However, it has been recently proposed (269) that 
rather than accumulation of VLCFAs, impaired peroxisomal β-oxidation may affect 
eicosanoid catabolism and thereby sustaining inflammation, which has been shown to 
be a key factor in the pathogenesis of ALD and other neurodegenerative diseases, and 
CLA may enhance this process via activation of PPARα (269). Unlike the results 
obtained in liver of Zucker rats, our measurements show that high doses of dietary CLA 
do not influence retinol levels in human plasma. The reason could be due to the 
different source of vitamin A in humans, mainly as β-carotene, with respect to 
experimental animals mainly consisting of retinyl esters. Therefore, the hypothesis 
according to which CLA by enhancing RBP (265) influences retinol absorption and 
metabolism, may not be valid if the dietary source of vitamin A is β-carotene. 
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6.2 Impact of dietary CLA on endocannabinoids and their congeners. 
Few studies have examined the effects of dietary CLA supplementation on 
endocannabinoids AEA and 2AG, and their congeners PEA and OEA. Tsuyama et al. 
(247) reported reduced amounts of 2-AG in the cerebral cortex of mice fed with a 3% 
CLA rich diet, compared with a diet containing the same amount of LA instead CLA. 
The Authors didn’t find any significant variations of AEA, OEA, and PEA levels after 4 
weeks of CLA treatment. The reduction of 2 AG levels in the cerebral cortex of the 
brain were not found in the hypothalamus.  
Dietary CLA has been shown to exert peculiar biological effects in a concentration 
range of 0.5–1% (158). The fatty acid used as control in the paper of Tsuyama et al. 
(247) was LA, the biosynthetic precursor of AA. As a consequence, the CLA diet 
resulted 3% lower in LA than the control diet, probably influencing both brain AA and 
2-AG levels, independently of dietary CLA. The levels of endocannabinoids and their 
congeners are affected by the dietary content of PUFAs or by their essential 
biosynthetic precursors, as shown by Artman et al. (237). 
In the present work the possible effects of CLA on endocannabinoids have been 
investigated comparing different background diets in Zucker rats and in humans with 
high dietary CLA intake.  
Our experiments conducted on Zucker rats showed that CLA does not significantly alter 
the concentration of endocannabinoids in liver, however, we detected changes in the 
concentrations of OEA and PEA. Diets containing 1% CLA increased OEA levels in 
both POCLA and OFCLA treatments. The increase of OEA doesn’t seem due to a 
change in the fatty acid precursor OA, in fact PO and OF diet are rich in OA, and 
incorporation of CLA in the diet, doesn’t modify the dietary content of OA in the OF 
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and actually decrease it in the PO diet. The increase of OEA levels in the liver, may be 
explained by activation of PPARα (271) by CLA, and in the OF diet may further 
contribute the higher levels of n-3 PUFAs. It has been shown that OEA possesses anti-
lipogenic activity in hepatocytes, decreases food intake and body weight gain (201) 
through direct activation of PPARα. Therefore, this increase may also mediate the 
reduced daily food intake. On the other hand, PEA increased only with CLA feeding 
with ovine fat background diet. 
The action of CLA on PEA deserves further scrutiny for its anti-inflammatory 
properties via several molecular mechanisms, including direct action of PPARα (197), 
or increasing AEA activity at CB1, TRPV1 or PPARγ receptors (200).  
In humans, CLA influences fatty acid metabolism of n-3, n-6, and n-9 UFAs, while 
does not cause significant changes in the profile of endocannabinoids in human plasma 
compared to OA diet. This finding partly confirmed another study where 0.8g/d of CLA 
did not modify endocannabinoid profile (248). However, it has been shown that 
administration of cheese naturally enriched in CLA, ALA and VA in 
hypercholesterolemic and overweight individuals, decreased the levels of AEA, while 
CLA alone did not (248). We found however an increase, even though not significant, 
of OEA and PEA, which may have some implication for OEA anorectic properties 
making it a possible target in the strategies for the treatment of obesity, and for PEA as 
potential candidate in the prevention of inflammatory states characteristic of many 
chronic diseases.    
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Conclusions 
The main conclusions from the present work can be summarized as follows:  
• CLA affected body and liver weight irrespective of the background diets in Zucker 
rats. The decrease of liver weight was mainly due to a reduced deposition of lipids. 
• CLA intake perturbed liver fatty acid and retinol metabolism, with increased 
concentration of AA with both PO or OF diets, and DHA (about 25%) only when 
CLA was included in the OF diet. CLA intake resulted in a decrease of ∆9 
desaturase index in Zucker rat liver. In addition, CLA feeding in combination with 
PO diet increases retinol level in liver of Zucker rats. 
• In human plasma, CLA compared to OA significantly decrease the metabolism and 
the incorporation of the LA metabolites. CLA is less efficiently desaturated and 
elongated than LA but more than OA, and competes with LA for 
metabolism/incorporation of metabolites. CLA reducing n-6 HUFAs, which resulted 
in an increased n-3 HUFA score. Also, we confirmed that high doses of CLA reduce 
elongation of LCFAs. 
• CLA does not cause significant changes in the profile of endocannabinoids in liver 
of Zucker rats and human plasma, with only a small decrease in the levels of AEA 
in the OF diet, compared with the same enriched in 1% CLA in Zucker rat liver. 
Remarkable for the anorectic properties ascribed to OEA, CLA feeding in Zucker 
rats enhances its levels in both POCLA and OFCLA diets. Data in humans also 
show an increase, but not significantly, of OEA and PEA levels in plasma, 
compared to OA diet.  
• Based on the results obtained from this work, we demonstrated that the nutritional 
effect of CLA is strongly influenced by the background diet, which may also 
 84
explain the differences found between experimental animals and humans. Dietary 
CLA may exert its beneficial actions on human health and protection against some 
diseases, by improving n-6/n-3 HPUFA balance and sustaining PPARα activity, 
directly and indirectly through OEA and PEA, especially those characterized by 
chronic inflammation due to an  impaired body fat deposition.  
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